deoxyepinephrine has been researched along with Heart Failure in 149 studies
Deoxyepinephrine: Sympathomimetic, vasoconstrictor agent.
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| " PRIME II (The Second Perspective Randomised study of Ibopamine on Mortality and Efficacy) was a large international randomised double blind trial comparing the addition of ibopamine or placebo to the therapy of patients with advanced heart failure." | 9.09 | Achieving appropriate endpoints in heart failure trials: the PRIME-II protocol. The Second Perspective Randomised study of Ibopamine on Mortality and Efficacy. ( Charlesworth, A; Cowley, AJ; Hampton, JR; Kleber, FX; Van Veldhuisen, DJ, 1999) |
| "To evaluate the acute hemodynamic effects of ibopamine (IBO), captopril (CAP) and placebo (PLA) in patients with severe congestive heart failure at rest." | 9.08 | [Acute hemodynamic effects of ibopamine, captopril, and placebo in patients with severe heart failure]. ( Azevedo, JE; Campos Filho, O; Cantarelli, MJ; Carvalho, AC; de Almeida, DR; Martinez Filho, EE; Smith, AC, 1995) |
| "In patients with early stages of heart failure, digoxin may prevent a progressive deterioration in heart rate variability, whereas ibopamine does not show statistically significant effects." | 9.08 | Heart rate variability in patients with mild to moderate heart failure: effects of neurohormonal modulation by digoxin and ibopamine. The Dutch Ibopamine Multicenter Trial (DIMT) Study Group. ( Boomsma, F; Brouwer, J; Dunselman, PH; Haaksma, J; Lie, KI; Man in 't Veld, AJ; van Veldhuisen, DJ, 1995) |
| "Ibopamine has hemodynamic and neurohumoral effects potentially useful for the treatment of congestive heart failure (CHF), but its mechanism of action is not completely clear." | 9.08 | Dopaminergic drugs in congestive heart failure: hemodynamic and neuroendocrine responses to ibopamine, dopamine, and dihydroergotoxine. ( Cas, LD; Metra, M; Missale, C; Spano, PF, 1995) |
| ") active dopamine (DA) agonist ibopamine, we examined 10 patients with mild to moderate congestive heart failure (CHF), who were stable while treated with digoxin and diuretics." | 9.08 | Renal and systemic hemodynamic effects of ibopamine in patients with mild to moderate congestive heart failure. ( Girbes, AR; Lie, KI; Lieverse, AG; Meijer, S; Reitsma, WD; Smit, AJ; van Veldhuisen, DJ; Zijlstra, JG, 1995) |
| "The purpose of this study was to determine the additive value of ibopamine in heart failure patients who are treated with angiotensin-converting enzyme inhibitors." | 9.08 | Clinical and autonomic effects of ibopamine as adjunct to angiotensin-converting enzyme inhibitors in chronic heart failure. ( Girbes, AR; Kruik, J; Lie, KI; Szabó, BM; van der Burgh, PH; van Veldhuisen, DJ, 1996) |
| "Patients with advanced severe heart failure (New York Heart Association classes III and IV) and evidence of severe left-ventricular disease, who were already receiving optimum treatment for heart failure, were randomly allocated oral ibopamine 100 mg three times daily or placebo." | 9.08 | Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators. ( Ardia, A; Block, P; Cortina, A; Cowley, AJ; Cserhalmi, L; Follath, F; Hampton, JR; Jensen, G; Kayanakis, J; Kleber, FX; Lie, KI; Mancia, G; Skene, AM; van Veldhuisen, DJ, 1997) |
| "To determine the effects of ibopamine 100 mg three times daily compared with captopril 25 mg three times daily on exercise capacity in patients with chronic heart failure." | 9.08 | Comparison of captopril and ibopamine in mild to moderate heart failure. ( Dohmen, HJ; Dunselman, PH; Poole-Wilson, PA, 1997) |
| "To determine the acute haemodynamic response of a single dose co-administration of ibopamine plus prazosin in patients with congestive heart failure." | 9.08 | Evaluation of ibopamine plus prazosin in congestive heart failure. ( Mitha, AS; Naidoo, DP; Rocke, A, 1998) |
| "To evaluate the effect on symptoms, exercise capacity (stress test) and myocardial response (Echo, and Holter) of ibopamine or captopril in patients with congestive heart failure." | 9.07 | [Comparative study between ibopamine and captopril in mild and moderate heart failure. A double-blind study]. ( Arcensio, SR; Arteaga, E; Barretto, AC; Bellotti, G; da Luz, PL; Mady, C; Pileggi, F; Szambock, F, 1994) |
| "In order to compare ibopamine (IBO), a dopamine congener, with isosorbide mononitrate (ISMN) and to study their interaction in effects on the capacitance vasculature in congestive heart failure (CHF), a prospective, randomized, placebo-controlled, double-blind clinical trial was performed in 32 patients with New York Heart Association class II-IV CHF, randomly assigned to receive single oral doses of placebo, 200 mg IBO, 20 mg ISMN, or both IBO and ISMN." | 9.07 | Acute effect of ibopamine and isosorbide mononitrate on blood volume distribution in congestive heart failure. ( de Voogt, WG; Groeneveld, AB; Hoekstra, OS; Holman, ND; Schneider, AJ; van der Meer, J, 1994) |
| "This study was conducted to determine the efficacy and safety of long-term treatment with the orally active dopamine agonist ibopamine in patients with mild to moderate chronic congestive heart failure and to compare the results with those of treatment with digoxin and placebo." | 9.07 | Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT). ( Brouwer, J; Dohmen, HJ; Dunselman, PH; Lie, KI; Lok, DJ; Man in 't Veld, AJ; Pasteuning, WH; Poortermans, JC; van Veldhuisen, DJ; Withagen, AJ, 1993) |
| "The effect of ibopamine and furosemide in 130 patients with NYHA Class I and II heart failure were studied in a parallel, double-blind, randomized placebo-controlled multi-centre trial." | 9.07 | The effects of oral ibopamine in patients with mild heart failure--a double blind placebo controlled comparison to furosemide. The Ibopamine Study Group. ( Parker, JO, 1993) |
| "The effects of acute and chronic ibopamine treatment on resting and exercise hemodynamics, exercise capacity and plasma catecholamines were evaluated in 25 patients with chronic heart failure, using a double-blind, parallel, placebo-controlled design." | 9.07 | Effects of acute and chronic ibopamine administration on resting and exercise hemodynamics, plasma catecholamines and functional capacity of patients with chronic congestive heart failure. ( Dei Cas, L; Metra, M; Visioli, O, 1992) |
| "To assess safety and efficacy of ibopamine, 200 mg TID, added to conventional treatment of congestive heart failure." | 9.07 | [Ibopamine in the treatment of congestive heart failure. Multicenter follow-up study]. ( Astorga, MA; Ceia, F; Coelho, EM; Fonseca, C; Gil, V; Gomes, RS; Gouveia, R; Luís, AS; Mota, E; Riva, E, 1992) |
| "Twenty-three patients with mild heart failure (I-II NYHA classes) on digitalis and diuretics were assigned to the following treatment in a random and double-blind fashion: ibopamine-captopril, ibopamine-placebo, captopril-placebo, and placebo-placebo." | 9.06 | Comparative effects of ibopamine and captopril in mild congestive heart failure. Focus on the long-term effects of inodilation on ventricular arrhythmias. ( Alunni, GF; Bardelli, G; Boschetti, E; Capponi, EA; Cocchieri, M; Del Favero, A; Fortunati, F; Regi, L, 1990) |
| "To examine the renal effects of ibopamine HCl we evaluated 15 patients with New York Heart Association Class II-III congestive heart failure and mild renal insufficiency (creatinine clearance [CLcr] = 45-85 ml min-1)." | 9.06 | Single-dose effects of ibopamine hydrochloride on renal function in patients with congestive heart failure. ( Cutler, RE; Goldberg, P; Green, JA; Hricik, D; Jarvis, RC; Kasmer, RJ; Munger, MA; Nara, AR, 1990) |
| "Diabetes mellitus was assessed by investigating 8 type I diabetic patients, in good metabolic control and with congestive heart failure, who were studied after 3 weeks of placebo and ibopamine (100 mg t." | 9.06 | Ibopamine does not affect insulin resistance in patients with type I diabetes. ( Benzi, L; Cecchetti, P; Ciccarone, AM; Cicchetti, V; Di Cianni, G; Navalesi, R; Sabino, F, 1990) |
| "Twelve outpatients with type II diabetes mellitus and mild clinical signs and history of cardiac failure were studied to assess the effects of ibopamine on glucose and lipid metabolism." | 9.06 | Safety of ibopamine in type II diabetic patients with mild chronic heart failure. A double-blind cross-over study. ( Cicchetti, V; DiCarlo, A; Giannarelli, R; Marchetti, P; Navalesi, R; Sabino, F, 1990) |
| "This multicentre, double-blind, double-dummy, randomised parallel group study in 247 patients with mild chronic congestive heart failure compared the efficacy and tolerability of ibopamine, hydrochlorothiazide (HCTZ), ibopamine plus HCTZ and placebo during an 8-week treatment period." | 9.06 | Treatment of mild chronic congestive heart failure with ibopamine, hydrochlorothiazide, ibopamine plus hydrochlorothiazide or placebo. A double-blind comparative study. ( Kleber, FX; Thyroff-Friesinger, U, 1990) |
| " in comparison to placebo and open titrated digoxin in patients with mild congestive heart failure NYHA class I and II." | 9.06 | Ibopamine versus digoxin in the treatment of mild congestive heart failure. A double-blind, randomized, placebo-controlled trial. ( Kleber, FX; Thyroff-Friesinger, U, 1990) |
| " In this study we evaluated the effects of dopamine and the dopaminergic agonists ibopamine and dihydroergotoxine on aldosterone secretion and plasma renin activity in 13 patients with chronic heart failure." | 9.06 | Inhibition of aldosterone secretion by dopamine, ibopamine, and dihydroergotoxine in patients with congestive heart failure. ( Dei Cas, L; Memo, M; Metra, M; Missale, C; Sigala, S; Spano, PF, 1989) |
| "Ibopamine, a dopamine derivative suitable for oral administration, is reported to improve cardiac function in patients with chronic heart failure." | 9.06 | Ibopamine vs. digoxin in chronic heart failure: a double-blind, crossover study. ( Alicandri, C; Boni, E; Fariello, R; Muiesan, G; Zaninelli, A, 1989) |
| "This randomized, double-blind, placebo-controlled, multicenter trial compared the effects of treatment with ibopamine with those of placebo in patients with severe heart failure who still showed symptoms although they were receiving standard therapy with digitalis and diuretics." | 9.06 | The long-term efficacy of ibopamine in treating patients with severe heart failure: a multicenter investigation. ( Bonaduce, A; Cacciapuoti, F; Canale, C; Caponnetto, S; Cappello, C; Condorelli, M; Mattioli, G; Montemurro, A; Terrachini, V; Varricchio, M, 1989) |
| "Under double-blind conditions, 150 mg of ibopamine (di-isobutyric ester of N-methyldopamine) or placebo were given orally to 11 patients with congestive heart failure; after 3 hours, 50 mg of sulpiride were administered intramuscularly." | 9.06 | Peripheral hemodynamic effects of ibopamine in patients with congestive heart failure. A placebo-controlled, double-blind study. ( Aggio, S; Ansani, L; Baracca, E; Ghirardi, P; Longhini, C; Musacci, GF; Toselli, T, 1989) |
| "Ibopamine is a dopaminergic and adrenergic receptor agonist, which is active in the treatment of congestive heart failure." | 9.06 | Influence of ibopamine on heart rate and arrhythmic pattern in patients with congestive heart failure. A double-blind multicentre study. ( , 1989) |
| "The substitution of digoxin with ibopamine, a new inotropic and vasodilating agent, was evaluated in a multicenter study in 58 patients with mild-to-moderate congestive heart failure, stabilized on diuretics, and digoxin therapy." | 9.06 | Ibopamine as a substitute for digitalis in patients with congestive heart failure on chronic digoxin therapy. Smith Kline and French Ibopamine Group. ( Abbondati, G; Cavalli, A; Fuccella, LM; Riva, E; Schleman, M, 1989) |
| "The effects of ibopamine and furosemide on renal function given alone and in combination at single doses were studied in 6 men and 6 women aged 45 to 73 years with chronic congestive heart failure of NYHA class II." | 9.06 | Effects of ibopamine in combination with furosemide on renal function in patients with chronic congestive heart failure. ( Carini, L; Castini, D; Mazzola, C; Moreo, A; Salvadeo, A; Segagni, S; Segalini, G; Villa, G; Vitolo, E, 1988) |
| "A multicenter double-blind placebo-controlled investigation was carried out in 42 patients with severe congestive heart failure who were given ibopamine (SB-7505), the 3,4-diisobutyryl ester of N-methyldopamine, for a period of 10 days in addition to previous treatment with digitalis and diuretics." | 9.06 | Positive inotropic effects of ibopamine in patients with congestive heart failure. A multicenter investigation. ( Allegro, A; Bellotti, G; Boccanelli, A; Caponnetto, S; Cataldi, A; Gambelli, G; Portioli, I; Prati, PL; Salvemini, M; Zacharo, E, 1986) |
| "Ibopamine, the most widely studied dopaminergic drug for the treatment of chronic heart failure, appears to have beneficial hemodynamic, renal, and neurohormonal effects in this setting." | 8.79 | Clinical efficacy of ibopamine in patients with chronic heart failure. ( Dei Cas, L; Metra, M, 1995) |
| " This review focuses on the safety of ibopamine in the treatment of chronic heart failure." | 8.78 | Ibopamine in the treatment of heart failure. ( Man in't Veld, AJ, 1991) |
| "In acute studies ibopamine, an a selective dopamine agonist, induces moderate increases of GFR and ERPF, and a fall in plasma norepinephrine levels in patients with congestive heart failure (CHF)." | 7.69 | The effects of ibopamine on glomerular filtration rate and plasma norepinephrine remain preserved during prolonged treatment in patients with congestive heart failure. ( Girbes, AR; Lie, KI; Lieverse, AG; Meijer, S; Reitsma, WD; Smit, AJ; Van Veldhuisen, DJ; Zijlstra, JG, 1995) |
| "The effects of a single dose of ibopamine on renal haemodynamics, sodium excretion, blood pressure (BP) and heart rate (HR) were investigated in 10 patients (aged 52-82 years) with severe congestive heart failure (CHF) who were in NYHA class IV." | 7.68 | Effects of ibopamine on renal haemodynamics in patients with severe congestive heart failure. ( Girbes, AR; Kalisvaart, CJ; Pasteuning, WH; Reitsma, WD; Smit, AJ; Tan, ET; Van Veldhuisen, DJ, 1993) |
| "Reversible leukopenia was documented in an 81-year-old woman treated with adjunctive ibopamine 100 mg t." | 7.68 | Ibopamine-induced reversible leukopenia during treatment for congestive heart failure. ( Bucx, JJ; Dankbaar, H; Huizing, G; Said, SA; van Gilst, WH, 1993) |
| "Increased plasma noradrenaline concentrations in rats with myocardial infarction and aortic stenosis were reduced by ibopamine." | 7.68 | Endothelium dependent relaxation in two different models of chronic heart failure and the effect of ibopamine. ( Buikema, H; de Smet, BJ; Lie, KI; Scholtens, E; van Gilst, WH; van Veldhuisen, DJ; Wesseling, H, 1993) |
| "Programmed electrical stimulation was performed in 12 patients with moderate to severe congestive heart failure and ventricular tachycardia (VT) to study possible arrhythmogenic properties of ibopamine, a new orally active dopamine agonist." | 7.68 | Electrophysiologic profile of ibopamine in patients with congestive heart failure and ventricular tachycardia and relation to its effects on hemodynamics and plasma catecholamines. ( Crijns, HJ; Girbes, AR; Lie, KI; Tobé, TJ; Van Veldhuisen, DJ; Wiesfeld, AC, 1991) |
| " Ibopamine is a new orally active inodilator, which is developed for the treatment of congestive heart failure (CHF)." | 7.68 | Efficacy and safety of ibopamine in congestive heart failure. ( Crijns, HJ; de Graeff, PA; Girbes, AR; Lie, KI; Smit, AJ; van Veldhuisen, DJ, 1990) |
| "Ten patients suffering from refractory congestive heart failure were treated orally with Ibopamine 100 mg." | 7.67 | Haemodynamic evaluation of ibopamine in severe congestive heart failure. ( Forattini, C; Gabellini, A; Reffo, GC; Turrin, M, 1984) |
| "The hemodynamic and metabolic effects of ibopamine, an orally active 3,4-diisobutylic ester of N-methyl-dopamine, at rest and during exercise, were evaluated in 8 patients with severe congestive heart failure, initially at 2 hrs after oral 100 mg and after 4 weeks of maintenance therapy (100 mg, 3 times a day)." | 7.67 | [Acute and chronic effects of a new oral inotropic agent, ibopamine hydrochloride, on hemodynamic and metabolic responses to ergometer exercise in patients with severe congestive heart failure]. ( Hamada, M; Iwata, J; Kakuta, Y; Kasai, A; Konishi, T; Morimoto, Y; Nagano, K; Nakano, T; Umino, M, 1989) |
| "The acute effect of a single oral 100 mg dose of ibopamine on systolic and diastolic left ventricular function in nine patients with congestive heart failure was assessed by quantitative M-mode and pulsed Doppler echocardiography." | 7.67 | Noninvasive assessment of diastolic and systolic properties of ibopamine in patients with congestive heart failure. ( Byers, SL; Chaitman, BR; Labovitz, AJ; Mrosek, D; Stoddard, MF, 1989) |
| "A group of 36 patients with cor pulmonale chronicum were treated for 12 months with ibopamine, a dopamine-related drug, orally active, suitable for the long-term therapy of congestive heart failure." | 7.67 | Treatment of heart failure following chronic cor pulmonale with ibopamine. ( Bianco, L; Cantoni, V; Cicchetti, V; Ghirardi, P; Marchetti, GV; Sabino, F, 1988) |
| "The pharmacokinetics of ibopamine after single and multiple dosing was studied in 20 patients with congestive heart failure (CHF) of NYHA functional class II." | 7.67 | Ibopamine kinetics after single and multiple dosing in patients with congestive heart failure. ( Azzollini, F; De Caro, L; Lodola, E; Longo, A; Pelosi, G; Rolandi, E; Ventresca, GP, 1988) |
| "The kinetics of ibopamine, the 3,4-diisobutyryl ester of N-methyldopamine (epinine), was assessed in 27 patients with congestive heart failure (CHF) and 8 healthy normal subjects (NS)." | 7.67 | Ibopamine kinetics after a single oral dose in patients with congestive heart failure. ( Azzollini, F; Castelnovo, P; Cattò, G; Iacuitti, G; Longo, A; Pataccini, R; Pelosi, G; Picca, M; Pocchiari, F; Ventresca, GP, 1988) |
| "Acute effects of 200 mg of orally given 4-[2-(methylamino)ethyl]-o-phenylene diisobutyrate hydrochloride (ibopamine hydrochloride) which is a new diisobutyric ester of N-methyldopamine, on hemodynamics and metabolism were evaluated in 11 patients with severe heart failure (New York Heart Association class IV)." | 7.67 | Acute effects of ibopamine hydrochloride on hemodynamics, plasma catecholamine levels, renin activity, aldosterone, metabolism and blood gas in patients with severe congestive heart failure. ( Kakuta, Y; Kanamaru, M; Kodera, T; Konishi, T; Morimoto, Y; Nakano, T; Takezawa, H, 1986) |
| "The aim of the present investigation was to evaluate the acute hemodynamic effects of a single oral dose of 200 mg ibopamine (SB-7505), the 3,4-diisobutyryl ester of N-methyldopamine (epinine) in 11 patients with congestive heart failure (CHF) and to compare the influence of dopamine infusion and oral ibopamine on left ventricular function." | 7.67 | Evaluation of acute hemodynamic effects and pharmacokinetic behaviour of ibopamine in patients with severe heart failure. ( Colombo, G; De Vita, C; Devizzi, S; Palvarini, M; Pataccini, R; Pocchiari, F; Triulzi, E, 1986) |
| "The hemodynamic effects of ibopamine (SB-7505), the orally active 3,4-diisobutyryl ester of N-methyldopamine, were studied in 12 patients with congestive heart failure (CHF) after acute dosing, after 20 days of maintenance therapy and after 20 days of drug discontinuation." | 7.67 | Hemodynamic evaluation during exercise test after acute and chronic ibopamine treatment in patients with congestive heart failure. ( Bramucci, E; Gavazzi, A; Mussini, A, 1986) |
| "Peripheral hemodynamics were studied using strain gauge plethysmography in patients with congestive heart failure after administration of ibopamine (SB-7505), the orally active 3,4-diisobutyryl ester of N-methyldopamine, a dopaminergic agonist, and of sulpiride, a specific dopaminergic antagonist." | 7.67 | Effects of ibopamine on peripheral hemodynamics: a strain gauge plethysmographic study in patients with congestive heart failure. ( Aggio, S; Ansani, L; Baracca, E; Longhini, C; Musacci, GF; Toselli, T, 1986) |
| "50 patients with congestive heart failure underwent monitored long-term treatment aimed at evaluating the effect of ibopamine (SB-7505), the 3,4-diisobutyryl ester of N-methyldopamine, on their condition." | 7.67 | Monitored long-term treatment with ibopamine in patients suffering from severe congestive heart failure. ( Avanzini, Z; Bellogini, GC; Brusoni, B; Ciampani, N; Dei Cas, L; Gazzola, U; Maggi, GC; Mangiavacchi, M; Metra, M; Pinca, L, 1986) |
| "N-Methyldopamine (epinine), one of the few modifications of the dopamine (DA) molecule that retains agonist activity at the DA1 receptor, was administered orally as the diisobutyric ester, ibopamine (100, 200, and 300 mg), to 15 patients with congestive heart failure." | 7.67 | Effects of long-term therapy with oral ibopamine on resting hemodynamics and exercise capacity in patients with heart failure: relationship to the generation of N-methyldopamine and to plasma norepinephrine levels. ( Douglas, FL; Goldberg, LI; Karrison, T; Rajfer, SI; Rossen, JD, 1986) |
| "Ten patients with congestive heart failure (CHF), in III and IV NYHA Class, were treated orally with a single dose of ibopamine ranging from 1." | 7.67 | Acute haemodynamic effects of ibopamine in patients with severe congestive heart failure. ( Bianco, L; Brusoni, B; Col, J; Dei Cas, L; Ghirardi, P; Mangiavacchi, M; Metra, M, 1985) |
| "The acute effects of ibopamine, a new, orally active dopaminergic agent, were assessed invasively in 8 patients with congestive heart failure (NYHA Class IV)." | 7.66 | Ibopamine in very severe congestive heart failure: pilot haemodynamic invasive assessment. ( Col, J; Mievis, E; Reynaert, M, 1983) |
| " The results rather suggest that long-term treatment with ibopamine affords an increase in survival and a delay in the progression of the disease, without adverse effects on cardiac rhythm and myocardial oxygen balance, and with a general improvement in the patients' quality of life." | 6.67 | Safety of ibopamine therapy in congestive heart failure. Ibopamine cohort study: baseline and 1-year results. ( Cesana, B; Ferrari, V; Licciardello, L; Sher, D; Sirtori, F, 1991) |
| "Ibopamine is a novel oral dopamine analogue with positive inotropy and diuretic effects." | 6.67 | [Renal effects of ibopamine in comparison with furosemide in patients with mild heart failure]. ( Gerzer, R; Theisen, K; Wehling, M; Weil, J; Zimmermann, J, 1990) |
| "Ibopamine does not produce undesirable renal side effects, but affects the neurohumoral status favourably." | 6.67 | Extracardial effects of oral ibopamine versus furosemide in patients with mild or moderate heart failure. A double-blind, randomized trial. ( Theisen, K; Wehling, M; Zimmermann, J, 1990) |
| "Ibopamine was well tolerated throughout the study." | 6.67 | Ibopamine in the treatment of mild chronic heart failure in elderly patients. A double-blind, placebo-controlled study. ( Azzolini, A; Colantoni, A; Guffanti, E; Pizzorni, C; Ronzitti, M; Tantalo, L, 1990) |
| "Ibopamine was given alone to 39 patients; the others were given the drug in association with digitalis, diuretics, and vasodilators." | 6.66 | Long-term therapy of chronic congestive heart failure with ibopamine: a multicenter trial. ( Cantoni, V; Cicchetti, V; Ghirardi, P; Marchetti, GV; Rolandi, E; Sabino, F, 1989) |
| "Ibopamine was then administered orally in single doses of 50 mg on day 2 and 100 mg on day 3." | 6.66 | Comparison of the acute hemodynamic effects of ibopamine and dopamine in chronic congestive heart failure. ( Castellaccio, M; Dore, L; Ibba, GV; Sannia, L, 1986) |
| "Ibopamine is a dopamine-like drug that shows mainly vasoactive properties, predominantly acting on dopamine1-(DA1-) and DA2-adrenoceptors." | 6.38 | Ibopamine in chronic congestive heart failure: hemodynamic and neurohumoral effects. ( López-Sendón, J, 1991) |
| "Ibopamine is an orally active dopaminergic substance and acts mainly as a vasodilator in patients with heart failure." | 6.38 | Effect of ibopamine, a dopamine congener, on arrhythmias in heart failure. ( Storstein, L, 1990) |
| "Ibopamine is a new, orally active dopamine-like drug with inotropic and vasoactive properties." | 6.38 | Hemodynamic and neurohumoral effects of ibopamine in patients with chronic congestive heart failure. ( López-Sendón, J, 1990) |
| " It is concluded that ibopamine is a safe drug which may become an interesting alternative or additive therapy for patients with chronic heart failure." | 6.38 | The safety profile of ibopamine, an alternative substance for treatment of chronic heart failure. ( Holubarsch, C; Just, H, 1990) |
| "Heart failure is a complex cardiovascular syndrome affording many pharmacotherapeutic targets." | 6.38 | Pharmacotherapeutic profile of ibopamine in heart failure. ( Taylor, SH, 1989) |
| " A daily levodopa dosage of at least 4 g appears to a prerequisite for long-term response to the drug." | 6.38 | Clinical relevance of long-term therapy with levodopa and orally active dopamine analogues in patients with chronic congestive heart failure. ( Hasenfuss, G; Just, H, 1989) |
| "Ibopamine was found to increase cardiac output and stroke index and to decrease systemic vascular resistance in this acute study." | 5.28 | Hemodynamic effects and pharmacokinetics of long-term therapy with ibopamine in patients with chronic heart failure. ( Itoh, H; Koike, A; Nakamura, S; Sato, Y; Taniguchi, K; Tsujibayashi, T, 1992) |
| "Ibopamine is a new orally active dopamine analogue with positive inotropic and vasodilating activity." | 5.28 | Ibopamine: long-term safety study in patients with congestive heart failure. The Italian Ibopamine Working Group. ( Abbondati, G; Cavalli, A; Cedrini, MC; Fuccella, LM; Riva, E; Schleman, M, 1989) |
| "Ibopamine is a new dopamine derivative, active on dopaminergic and beta-adrenergic receptors, whose hemodynamic activity has been acutely demonstrated." | 5.27 | Lack of tolerance development during chronic ibopamine administration to patients with congestive heart failure. ( Dei Cas, L; Manca, C; Metra, M; Nodari, S; Riva, S; Visioli, O, 1988) |
| " PRIME II (The Second Perspective Randomised study of Ibopamine on Mortality and Efficacy) was a large international randomised double blind trial comparing the addition of ibopamine or placebo to the therapy of patients with advanced heart failure." | 5.09 | Achieving appropriate endpoints in heart failure trials: the PRIME-II protocol. The Second Perspective Randomised study of Ibopamine on Mortality and Efficacy. ( Charlesworth, A; Cowley, AJ; Hampton, JR; Kleber, FX; Van Veldhuisen, DJ, 1999) |
| "To evaluate the acute hemodynamic effects of ibopamine (IBO), captopril (CAP) and placebo (PLA) in patients with severe congestive heart failure at rest." | 5.08 | [Acute hemodynamic effects of ibopamine, captopril, and placebo in patients with severe heart failure]. ( Azevedo, JE; Campos Filho, O; Cantarelli, MJ; Carvalho, AC; de Almeida, DR; Martinez Filho, EE; Smith, AC, 1995) |
| "In patients with early stages of heart failure, digoxin may prevent a progressive deterioration in heart rate variability, whereas ibopamine does not show statistically significant effects." | 5.08 | Heart rate variability in patients with mild to moderate heart failure: effects of neurohormonal modulation by digoxin and ibopamine. The Dutch Ibopamine Multicenter Trial (DIMT) Study Group. ( Boomsma, F; Brouwer, J; Dunselman, PH; Haaksma, J; Lie, KI; Man in 't Veld, AJ; van Veldhuisen, DJ, 1995) |
| "Ibopamine has hemodynamic and neurohumoral effects potentially useful for the treatment of congestive heart failure (CHF), but its mechanism of action is not completely clear." | 5.08 | Dopaminergic drugs in congestive heart failure: hemodynamic and neuroendocrine responses to ibopamine, dopamine, and dihydroergotoxine. ( Cas, LD; Metra, M; Missale, C; Spano, PF, 1995) |
| ") active dopamine (DA) agonist ibopamine, we examined 10 patients with mild to moderate congestive heart failure (CHF), who were stable while treated with digoxin and diuretics." | 5.08 | Renal and systemic hemodynamic effects of ibopamine in patients with mild to moderate congestive heart failure. ( Girbes, AR; Lie, KI; Lieverse, AG; Meijer, S; Reitsma, WD; Smit, AJ; van Veldhuisen, DJ; Zijlstra, JG, 1995) |
| "The purpose of this study was to determine the additive value of ibopamine in heart failure patients who are treated with angiotensin-converting enzyme inhibitors." | 5.08 | Clinical and autonomic effects of ibopamine as adjunct to angiotensin-converting enzyme inhibitors in chronic heart failure. ( Girbes, AR; Kruik, J; Lie, KI; Szabó, BM; van der Burgh, PH; van Veldhuisen, DJ, 1996) |
| "Patients with advanced severe heart failure (New York Heart Association classes III and IV) and evidence of severe left-ventricular disease, who were already receiving optimum treatment for heart failure, were randomly allocated oral ibopamine 100 mg three times daily or placebo." | 5.08 | Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators. ( Ardia, A; Block, P; Cortina, A; Cowley, AJ; Cserhalmi, L; Follath, F; Hampton, JR; Jensen, G; Kayanakis, J; Kleber, FX; Lie, KI; Mancia, G; Skene, AM; van Veldhuisen, DJ, 1997) |
| "We compared the effects of the orally active dopamine agonist ibopamine with the loop diuretic frusemide as first-line therapy in patients with mild congestive heart failure." | 5.08 | A double-blind, cross-over comparison of the effects of a loop diuretic and a dopamine receptor agonist as first line therapy in patients with mild congestive heart failure. ( Andrews, R; Charlesworth, A; Cowley, AJ; Evans, A, 1997) |
| "To determine the effects of ibopamine 100 mg three times daily compared with captopril 25 mg three times daily on exercise capacity in patients with chronic heart failure." | 5.08 | Comparison of captopril and ibopamine in mild to moderate heart failure. ( Dohmen, HJ; Dunselman, PH; Poole-Wilson, PA, 1997) |
| "To determine the acute haemodynamic response of a single dose co-administration of ibopamine plus prazosin in patients with congestive heart failure." | 5.08 | Evaluation of ibopamine plus prazosin in congestive heart failure. ( Mitha, AS; Naidoo, DP; Rocke, A, 1998) |
| "To evaluate the effect on symptoms, exercise capacity (stress test) and myocardial response (Echo, and Holter) of ibopamine or captopril in patients with congestive heart failure." | 5.07 | [Comparative study between ibopamine and captopril in mild and moderate heart failure. A double-blind study]. ( Arcensio, SR; Arteaga, E; Barretto, AC; Bellotti, G; da Luz, PL; Mady, C; Pileggi, F; Szambock, F, 1994) |
| "In order to compare ibopamine (IBO), a dopamine congener, with isosorbide mononitrate (ISMN) and to study their interaction in effects on the capacitance vasculature in congestive heart failure (CHF), a prospective, randomized, placebo-controlled, double-blind clinical trial was performed in 32 patients with New York Heart Association class II-IV CHF, randomly assigned to receive single oral doses of placebo, 200 mg IBO, 20 mg ISMN, or both IBO and ISMN." | 5.07 | Acute effect of ibopamine and isosorbide mononitrate on blood volume distribution in congestive heart failure. ( de Voogt, WG; Groeneveld, AB; Hoekstra, OS; Holman, ND; Schneider, AJ; van der Meer, J, 1994) |
| "This study was conducted to determine the efficacy and safety of long-term treatment with the orally active dopamine agonist ibopamine in patients with mild to moderate chronic congestive heart failure and to compare the results with those of treatment with digoxin and placebo." | 5.07 | Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT). ( Brouwer, J; Dohmen, HJ; Dunselman, PH; Lie, KI; Lok, DJ; Man in 't Veld, AJ; Pasteuning, WH; Poortermans, JC; van Veldhuisen, DJ; Withagen, AJ, 1993) |
| "The effect of ibopamine and furosemide in 130 patients with NYHA Class I and II heart failure were studied in a parallel, double-blind, randomized placebo-controlled multi-centre trial." | 5.07 | The effects of oral ibopamine in patients with mild heart failure--a double blind placebo controlled comparison to furosemide. The Ibopamine Study Group. ( Parker, JO, 1993) |
| "The effects of acute and chronic ibopamine treatment on resting and exercise hemodynamics, exercise capacity and plasma catecholamines were evaluated in 25 patients with chronic heart failure, using a double-blind, parallel, placebo-controlled design." | 5.07 | Effects of acute and chronic ibopamine administration on resting and exercise hemodynamics, plasma catecholamines and functional capacity of patients with chronic congestive heart failure. ( Dei Cas, L; Metra, M; Visioli, O, 1992) |
| "To assess safety and efficacy of ibopamine, 200 mg TID, added to conventional treatment of congestive heart failure." | 5.07 | [Ibopamine in the treatment of congestive heart failure. Multicenter follow-up study]. ( Astorga, MA; Ceia, F; Coelho, EM; Fonseca, C; Gil, V; Gomes, RS; Gouveia, R; Luís, AS; Mota, E; Riva, E, 1992) |
| "Twenty-three patients with mild heart failure (I-II NYHA classes) on digitalis and diuretics were assigned to the following treatment in a random and double-blind fashion: ibopamine-captopril, ibopamine-placebo, captopril-placebo, and placebo-placebo." | 5.06 | Comparative effects of ibopamine and captopril in mild congestive heart failure. Focus on the long-term effects of inodilation on ventricular arrhythmias. ( Alunni, GF; Bardelli, G; Boschetti, E; Capponi, EA; Cocchieri, M; Del Favero, A; Fortunati, F; Regi, L, 1990) |
| "To examine the renal effects of ibopamine HCl we evaluated 15 patients with New York Heart Association Class II-III congestive heart failure and mild renal insufficiency (creatinine clearance [CLcr] = 45-85 ml min-1)." | 5.06 | Single-dose effects of ibopamine hydrochloride on renal function in patients with congestive heart failure. ( Cutler, RE; Goldberg, P; Green, JA; Hricik, D; Jarvis, RC; Kasmer, RJ; Munger, MA; Nara, AR, 1990) |
| "Diabetes mellitus was assessed by investigating 8 type I diabetic patients, in good metabolic control and with congestive heart failure, who were studied after 3 weeks of placebo and ibopamine (100 mg t." | 5.06 | Ibopamine does not affect insulin resistance in patients with type I diabetes. ( Benzi, L; Cecchetti, P; Ciccarone, AM; Cicchetti, V; Di Cianni, G; Navalesi, R; Sabino, F, 1990) |
| "Twelve outpatients with type II diabetes mellitus and mild clinical signs and history of cardiac failure were studied to assess the effects of ibopamine on glucose and lipid metabolism." | 5.06 | Safety of ibopamine in type II diabetic patients with mild chronic heart failure. A double-blind cross-over study. ( Cicchetti, V; DiCarlo, A; Giannarelli, R; Marchetti, P; Navalesi, R; Sabino, F, 1990) |
| "This multicentre, double-blind, double-dummy, randomised parallel group study in 247 patients with mild chronic congestive heart failure compared the efficacy and tolerability of ibopamine, hydrochlorothiazide (HCTZ), ibopamine plus HCTZ and placebo during an 8-week treatment period." | 5.06 | Treatment of mild chronic congestive heart failure with ibopamine, hydrochlorothiazide, ibopamine plus hydrochlorothiazide or placebo. A double-blind comparative study. ( Kleber, FX; Thyroff-Friesinger, U, 1990) |
| " in comparison to placebo and open titrated digoxin in patients with mild congestive heart failure NYHA class I and II." | 5.06 | Ibopamine versus digoxin in the treatment of mild congestive heart failure. A double-blind, randomized, placebo-controlled trial. ( Kleber, FX; Thyroff-Friesinger, U, 1990) |
| " In this study we evaluated the effects of dopamine and the dopaminergic agonists ibopamine and dihydroergotoxine on aldosterone secretion and plasma renin activity in 13 patients with chronic heart failure." | 5.06 | Inhibition of aldosterone secretion by dopamine, ibopamine, and dihydroergotoxine in patients with congestive heart failure. ( Dei Cas, L; Memo, M; Metra, M; Missale, C; Sigala, S; Spano, PF, 1989) |
| "Ibopamine, a dopamine derivative suitable for oral administration, is reported to improve cardiac function in patients with chronic heart failure." | 5.06 | Ibopamine vs. digoxin in chronic heart failure: a double-blind, crossover study. ( Alicandri, C; Boni, E; Fariello, R; Muiesan, G; Zaninelli, A, 1989) |
| "This randomized, double-blind, placebo-controlled, multicenter trial compared the effects of treatment with ibopamine with those of placebo in patients with severe heart failure who still showed symptoms although they were receiving standard therapy with digitalis and diuretics." | 5.06 | The long-term efficacy of ibopamine in treating patients with severe heart failure: a multicenter investigation. ( Bonaduce, A; Cacciapuoti, F; Canale, C; Caponnetto, S; Cappello, C; Condorelli, M; Mattioli, G; Montemurro, A; Terrachini, V; Varricchio, M, 1989) |
| "Under double-blind conditions, 150 mg of ibopamine (di-isobutyric ester of N-methyldopamine) or placebo were given orally to 11 patients with congestive heart failure; after 3 hours, 50 mg of sulpiride were administered intramuscularly." | 5.06 | Peripheral hemodynamic effects of ibopamine in patients with congestive heart failure. A placebo-controlled, double-blind study. ( Aggio, S; Ansani, L; Baracca, E; Ghirardi, P; Longhini, C; Musacci, GF; Toselli, T, 1989) |
| "Ibopamine is a dopaminergic and adrenergic receptor agonist, which is active in the treatment of congestive heart failure." | 5.06 | Influence of ibopamine on heart rate and arrhythmic pattern in patients with congestive heart failure. A double-blind multicentre study. ( , 1989) |
| "The substitution of digoxin with ibopamine, a new inotropic and vasodilating agent, was evaluated in a multicenter study in 58 patients with mild-to-moderate congestive heart failure, stabilized on diuretics, and digoxin therapy." | 5.06 | Ibopamine as a substitute for digitalis in patients with congestive heart failure on chronic digoxin therapy. Smith Kline and French Ibopamine Group. ( Abbondati, G; Cavalli, A; Fuccella, LM; Riva, E; Schleman, M, 1989) |
| "The effects of ibopamine and furosemide on renal function given alone and in combination at single doses were studied in 6 men and 6 women aged 45 to 73 years with chronic congestive heart failure of NYHA class II." | 5.06 | Effects of ibopamine in combination with furosemide on renal function in patients with chronic congestive heart failure. ( Carini, L; Castini, D; Mazzola, C; Moreo, A; Salvadeo, A; Segagni, S; Segalini, G; Villa, G; Vitolo, E, 1988) |
| "A multicenter double-blind placebo-controlled investigation was carried out in 42 patients with severe congestive heart failure who were given ibopamine (SB-7505), the 3,4-diisobutyryl ester of N-methyldopamine, for a period of 10 days in addition to previous treatment with digitalis and diuretics." | 5.06 | Positive inotropic effects of ibopamine in patients with congestive heart failure. A multicenter investigation. ( Allegro, A; Bellotti, G; Boccanelli, A; Caponnetto, S; Cataldi, A; Gambelli, G; Portioli, I; Prati, PL; Salvemini, M; Zacharo, E, 1986) |
| "This study compares the effects of digoxin, placebo and ibopamine (SB-7505), the orally active 3,4-diisobutyryl ester of N-methyl-dopamine, on exercise tolerance and cardiac rhythm of 14 patients whose left ventricular heart failure (end-diastolic pressure, 26." | 5.06 | Effects of digoxin, placebo and ibopamine on exercise tolerance and cardiac rhythm of patients with chronic post-infarct left ventricular failure. ( Brusoni, B; Cadel, A; Carati, L; Fanciulli, R; Osculati, G; Pirelli, P; Rovati, A; Valagussa, F, 1986) |
| "The effects of Ibopamine, a new orally active dopaminergic agent, on cardiac performance were studied both in a group of healthy volunteers and in a group of patients with congestive heart failure (CHF), using non-invasive methods, such as echocardiography and polygraphy." | 5.05 | [Echocardiographic and polygraphic study of acute/effects of Ibopamine on cardiac performance]. ( Brusoni, B; Cadel, A; Ladelli, L; Mangiavacchi, M; Pezzano, A; Sala, G, 1983) |
| "Ibopamine, the most widely studied dopaminergic drug for the treatment of chronic heart failure, appears to have beneficial hemodynamic, renal, and neurohormonal effects in this setting." | 4.79 | Clinical efficacy of ibopamine in patients with chronic heart failure. ( Dei Cas, L; Metra, M, 1995) |
| " This review focuses on the safety of ibopamine in the treatment of chronic heart failure." | 4.78 | Ibopamine in the treatment of heart failure. ( Man in't Veld, AJ, 1991) |
| "Ibopamine (IP) is a novel dopamine analogue for which beneficial effects have been shown in chronic heart failure." | 4.78 | [Ibopamine--acute hemodynamic, renal and neurohumoral effects]. ( Theisen, K; Wehling, M, 1991) |
| " Following an outline of the medicinal chemistry bases of the development of these prodrugs, laboratory and clinical pharmacology of ibopamine, levodopa, gludopa, and TA-870 are reviewed, pointing out the interesting indications of various preliminary studies in heart failure, essential hypertension, and renal failure on the one hand, and the extensive therapeutic experience with ibopamine as an "inodilator" in the chronic treatment of congestive heart failure on the other hand." | 4.77 | Cardiovascular and renal action of dopaminergic prodrugs. ( Casagrande, C; Ferrini, R; Merlo, L; Miragoli, G; Semeraro, C, 1989) |
| "Ibopamine is an orally effective derivative of dopamine capable of eliciting peripheral and renal vasodilating activity and positive inotropic action." | 3.76 | Ibopamine--how should it be used? ( Bussmann, WD; Frik, R; Wienhöfer, K, 1988) |
| "1146 patients with congestive heart failure who were prescribed ibopamine at least once and for whom medication history and medical data were available." | 3.71 | Confounding by contraindication in a nationwide cohort study of risk for death in patients taking ibopamine. ( Feenstra, H; Grobbee, RE; in't Veld, BA; Stricker, BH, 2001) |
| "In September 1995, the indication for the oral dopamine agonist ibopamine was restricted in the Netherlands and in several other European countries to patients with NYHA-class II heart failure as a result of an interim analysis of the PRIME-II trial." | 3.70 | Risk factors for mortality in users of ibopamine. ( Feenstra, J; Grobbee, DE; in't Veld, BA; Stricker, BH; van der Linden, PD, 1998) |
| "In acute studies ibopamine, an a selective dopamine agonist, induces moderate increases of GFR and ERPF, and a fall in plasma norepinephrine levels in patients with congestive heart failure (CHF)." | 3.69 | The effects of ibopamine on glomerular filtration rate and plasma norepinephrine remain preserved during prolonged treatment in patients with congestive heart failure. ( Girbes, AR; Lie, KI; Lieverse, AG; Meijer, S; Reitsma, WD; Smit, AJ; Van Veldhuisen, DJ; Zijlstra, JG, 1995) |
| "NYHA classification and serum-creatinine levels were independent risk factors for death in patients with heart failure on ibopamine." | 3.69 | A nested case-control study on mortality in users of ibopamine. ( Feenstra, J; Grobbee, DE; Ottervanger, JP; Porsius, AJ; Stricker, BH, 1997) |
| "The effects of a single dose of ibopamine on renal haemodynamics, sodium excretion, blood pressure (BP) and heart rate (HR) were investigated in 10 patients (aged 52-82 years) with severe congestive heart failure (CHF) who were in NYHA class IV." | 3.68 | Effects of ibopamine on renal haemodynamics in patients with severe congestive heart failure. ( Girbes, AR; Kalisvaart, CJ; Pasteuning, WH; Reitsma, WD; Smit, AJ; Tan, ET; Van Veldhuisen, DJ, 1993) |
| "Reversible leukopenia was documented in an 81-year-old woman treated with adjunctive ibopamine 100 mg t." | 3.68 | Ibopamine-induced reversible leukopenia during treatment for congestive heart failure. ( Bucx, JJ; Dankbaar, H; Huizing, G; Said, SA; van Gilst, WH, 1993) |
| "Increased plasma noradrenaline concentrations in rats with myocardial infarction and aortic stenosis were reduced by ibopamine." | 3.68 | Endothelium dependent relaxation in two different models of chronic heart failure and the effect of ibopamine. ( Buikema, H; de Smet, BJ; Lie, KI; Scholtens, E; van Gilst, WH; van Veldhuisen, DJ; Wesseling, H, 1993) |
| "Ibopamine is an active dopamine analogue leading to improved renal perfusion and afterload reduction in heart failure." | 3.68 | Ibopamine as a valuable adjunct and substitute for dopamine in bridging therapy before heart transplantation. ( Cabell, B; Glogar, D; Kleber, FX; Sabin, GV; Thyroff-Friesinger, U, 1992) |
| "Twenty-six patients with mild to moderate heart failure were studied to determine the effects of epinine infusion (at a rate producing plasma levels similar to those measured after oral administration of 100 mg of the prodrug ibopamine) on left ventricular (LV) function (14 patients), and coronary flow and circulating catecholamines (12 patients)." | 3.68 | Effects of intravenous epinine administration on left ventricular systolic performance, coronary hemodynamics, and circulating catecholamines in patients with heart failure. ( Lotti, G; Musso, NR; Pouleur, H; Raigoso, J; Rousseau, MF; van Eyll, C; Van Mechelen, H, 1992) |
| "Programmed electrical stimulation was performed in 12 patients with moderate to severe congestive heart failure and ventricular tachycardia (VT) to study possible arrhythmogenic properties of ibopamine, a new orally active dopamine agonist." | 3.68 | Electrophysiologic profile of ibopamine in patients with congestive heart failure and ventricular tachycardia and relation to its effects on hemodynamics and plasma catecholamines. ( Crijns, HJ; Girbes, AR; Lie, KI; Tobé, TJ; Van Veldhuisen, DJ; Wiesfeld, AC, 1991) |
| "In order to confirm the efficacy of ibopamine for the management of congestive heart failure, as shown by the disappearance of clinical symptoms, the authors have assessed the cardiothoracic index before and after drug administration." | 3.68 | [Changes in the cardio-thoracic index during the treatment with ibopamine]. ( Bordoni, G; Castelli, N; Giannazzo, G; Mannolini, G; Pala, AM; Piccini, L, 1991) |
| " Ibopamine is a new orally active inodilator, which is developed for the treatment of congestive heart failure (CHF)." | 3.68 | Efficacy and safety of ibopamine in congestive heart failure. ( Crijns, HJ; de Graeff, PA; Girbes, AR; Lie, KI; Smit, AJ; van Veldhuisen, DJ, 1990) |
| "Ten patients suffering from refractory congestive heart failure were treated orally with Ibopamine 100 mg." | 3.67 | Haemodynamic evaluation of ibopamine in severe congestive heart failure. ( Forattini, C; Gabellini, A; Reffo, GC; Turrin, M, 1984) |
| "The hemodynamic and metabolic effects of ibopamine, an orally active 3,4-diisobutylic ester of N-methyl-dopamine, at rest and during exercise, were evaluated in 8 patients with severe congestive heart failure, initially at 2 hrs after oral 100 mg and after 4 weeks of maintenance therapy (100 mg, 3 times a day)." | 3.67 | [Acute and chronic effects of a new oral inotropic agent, ibopamine hydrochloride, on hemodynamic and metabolic responses to ergometer exercise in patients with severe congestive heart failure]. ( Hamada, M; Iwata, J; Kakuta, Y; Kasai, A; Konishi, T; Morimoto, Y; Nagano, K; Nakano, T; Umino, M, 1989) |
| "The acute effect of a single oral 100 mg dose of ibopamine on systolic and diastolic left ventricular function in nine patients with congestive heart failure was assessed by quantitative M-mode and pulsed Doppler echocardiography." | 3.67 | Noninvasive assessment of diastolic and systolic properties of ibopamine in patients with congestive heart failure. ( Byers, SL; Chaitman, BR; Labovitz, AJ; Mrosek, D; Stoddard, MF, 1989) |
| "A group of 36 patients with cor pulmonale chronicum were treated for 12 months with ibopamine, a dopamine-related drug, orally active, suitable for the long-term therapy of congestive heart failure." | 3.67 | Treatment of heart failure following chronic cor pulmonale with ibopamine. ( Bianco, L; Cantoni, V; Cicchetti, V; Ghirardi, P; Marchetti, GV; Sabino, F, 1988) |
| "The pharmacokinetics of ibopamine after single and multiple dosing was studied in 20 patients with congestive heart failure (CHF) of NYHA functional class II." | 3.67 | Ibopamine kinetics after single and multiple dosing in patients with congestive heart failure. ( Azzollini, F; De Caro, L; Lodola, E; Longo, A; Pelosi, G; Rolandi, E; Ventresca, GP, 1988) |
| "Eleven patients suffering from heart failure were treated with oral ibopamine, a di-isobutyric ester of N-methyldopamine, 100 mg three times a day for 1 week and 200 mg three times a day for 3 weeks." | 3.67 | Effect of ibopamine on the failing heart at rest and during isometric exercise: a noninvasive study. ( Lehto, H; Nieminen, MS; Partanen, J, 1988) |
| "The kinetics of ibopamine, the 3,4-diisobutyryl ester of N-methyldopamine (epinine), was assessed in 27 patients with congestive heart failure (CHF) and 8 healthy normal subjects (NS)." | 3.67 | Ibopamine kinetics after a single oral dose in patients with congestive heart failure. ( Azzollini, F; Castelnovo, P; Cattò, G; Iacuitti, G; Longo, A; Pataccini, R; Pelosi, G; Picca, M; Pocchiari, F; Ventresca, GP, 1988) |
| "Acute effects of 200 mg of orally given 4-[2-(methylamino)ethyl]-o-phenylene diisobutyrate hydrochloride (ibopamine hydrochloride) which is a new diisobutyric ester of N-methyldopamine, on hemodynamics and metabolism were evaluated in 11 patients with severe heart failure (New York Heart Association class IV)." | 3.67 | Acute effects of ibopamine hydrochloride on hemodynamics, plasma catecholamine levels, renin activity, aldosterone, metabolism and blood gas in patients with severe congestive heart failure. ( Kakuta, Y; Kanamaru, M; Kodera, T; Konishi, T; Morimoto, Y; Nakano, T; Takezawa, H, 1986) |
| "The aim of the present investigation was to evaluate the acute hemodynamic effects of a single oral dose of 200 mg ibopamine (SB-7505), the 3,4-diisobutyryl ester of N-methyldopamine (epinine) in 11 patients with congestive heart failure (CHF) and to compare the influence of dopamine infusion and oral ibopamine on left ventricular function." | 3.67 | Evaluation of acute hemodynamic effects and pharmacokinetic behaviour of ibopamine in patients with severe heart failure. ( Colombo, G; De Vita, C; Devizzi, S; Palvarini, M; Pataccini, R; Pocchiari, F; Triulzi, E, 1986) |
| "The hemodynamic effects of ibopamine (SB-7505), the orally active 3,4-diisobutyryl ester of N-methyldopamine, were studied in 12 patients with congestive heart failure (CHF) after acute dosing, after 20 days of maintenance therapy and after 20 days of drug discontinuation." | 3.67 | Hemodynamic evaluation during exercise test after acute and chronic ibopamine treatment in patients with congestive heart failure. ( Bramucci, E; Gavazzi, A; Mussini, A, 1986) |
| "Peripheral hemodynamics were studied using strain gauge plethysmography in patients with congestive heart failure after administration of ibopamine (SB-7505), the orally active 3,4-diisobutyryl ester of N-methyldopamine, a dopaminergic agonist, and of sulpiride, a specific dopaminergic antagonist." | 3.67 | Effects of ibopamine on peripheral hemodynamics: a strain gauge plethysmographic study in patients with congestive heart failure. ( Aggio, S; Ansani, L; Baracca, E; Longhini, C; Musacci, GF; Toselli, T, 1986) |
| "The purpose of this multicenter study was to evaluate the therapeutic efficacy of ibopamine (SB-7505), the 3,4-diisobutyrylester of N-methyldopamine, chronically administered to patients with severe congestive heart failure (CHF) in whom traditional therapy had been ineffective." | 3.67 | Multicenter study on the clinical efficacy of chronic ibopamine administration. ( Barilli, AC; Cavicchi, E; Dei Cas, L; Fracalossi, C; Lomanto, B; Longhini, C; Maggi, GC; Metra, M; Pinca, L; Santambrogio, S, 1986) |
| "50 patients with congestive heart failure underwent monitored long-term treatment aimed at evaluating the effect of ibopamine (SB-7505), the 3,4-diisobutyryl ester of N-methyldopamine, on their condition." | 3.67 | Monitored long-term treatment with ibopamine in patients suffering from severe congestive heart failure. ( Avanzini, Z; Bellogini, GC; Brusoni, B; Ciampani, N; Dei Cas, L; Gazzola, U; Maggi, GC; Mangiavacchi, M; Metra, M; Pinca, L, 1986) |
| "N-Methyldopamine (epinine), one of the few modifications of the dopamine (DA) molecule that retains agonist activity at the DA1 receptor, was administered orally as the diisobutyric ester, ibopamine (100, 200, and 300 mg), to 15 patients with congestive heart failure." | 3.67 | Effects of long-term therapy with oral ibopamine on resting hemodynamics and exercise capacity in patients with heart failure: relationship to the generation of N-methyldopamine and to plasma norepinephrine levels. ( Douglas, FL; Goldberg, LI; Karrison, T; Rajfer, SI; Rossen, JD, 1986) |
| "In 7 patients with congestive heart failure acute oral administration of ibopamine, a new dopamine derivative, induced a significant decrease in serum prolactin and aldosterone without affecting serum growth hormone or cortisol." | 3.67 | Inhibition of prolactin and aldosterone secretion by the dopamine derivative ibopamine. ( Barreca, T; Cantoni, V; Cicchetti, V; Franceschini, R; Gianrossi, R; Marchetti, G; Rolandi, E, 1986) |
| "Ten patients with congestive heart failure (CHF), in III and IV NYHA Class, were treated orally with a single dose of ibopamine ranging from 1." | 3.67 | Acute haemodynamic effects of ibopamine in patients with severe congestive heart failure. ( Bianco, L; Brusoni, B; Col, J; Dei Cas, L; Ghirardi, P; Mangiavacchi, M; Metra, M, 1985) |
| "The hemodynamic effects of combined administration of ibopamine (Ib) (150 mg orally) with nitroprusside (NP) (50-150 micrograms/min intravenously) were compared with those of NP alone in 17 patients with severe congestive heart failure due to coronary artery disease (7 patients) or idiopathic cardiomyopathy (10 patients)." | 3.67 | Hemodynamic advantage of combined administration of oral ibopamine and nitroprusside in patients with ischemic and idiopathic congestive cardiomyopathy. ( Cicogna, R; Dei Cas, L; Fappani, A; Manca, C; Metra, M; Riva, S; Visioli, O, 1985) |
| "The acute effects of ibopamine, a new, orally active dopaminergic agent, were assessed invasively in 8 patients with congestive heart failure (NYHA Class IV)." | 3.66 | Ibopamine in very severe congestive heart failure: pilot haemodynamic invasive assessment. ( Col, J; Mievis, E; Reynaert, M, 1983) |
| "Fifteen congestive heart failure patients (NYHA: class III or IV) were enrolled in the study and were classified into two groups." | 2.67 | Hemodynamic comparison of combined therapy by nitroglycerin tape and ibopamine with combination of nitroglycerin tape and nifedipine. ( Itoh, H; Taniguchi, K; Tsujibayashi, T, 1990) |
| " The results rather suggest that long-term treatment with ibopamine affords an increase in survival and a delay in the progression of the disease, without adverse effects on cardiac rhythm and myocardial oxygen balance, and with a general improvement in the patients' quality of life." | 2.67 | Safety of ibopamine therapy in congestive heart failure. Ibopamine cohort study: baseline and 1-year results. ( Cesana, B; Ferrari, V; Licciardello, L; Sher, D; Sirtori, F, 1991) |
| "Ibopamine is a novel oral dopamine analogue with positive inotropy and diuretic effects." | 2.67 | [Renal effects of ibopamine in comparison with furosemide in patients with mild heart failure]. ( Gerzer, R; Theisen, K; Wehling, M; Weil, J; Zimmermann, J, 1990) |
| "Ibopamine does not produce undesirable renal side effects, but affects the neurohumoral status favourably." | 2.67 | Extracardial effects of oral ibopamine versus furosemide in patients with mild or moderate heart failure. A double-blind, randomized trial. ( Theisen, K; Wehling, M; Zimmermann, J, 1990) |
| "Ibopamine was well tolerated throughout the study." | 2.67 | Ibopamine in the treatment of mild chronic heart failure in elderly patients. A double-blind, placebo-controlled study. ( Azzolini, A; Colantoni, A; Guffanti, E; Pizzorni, C; Ronzitti, M; Tantalo, L, 1990) |
| "Ibopamine was given alone to 39 patients; the others were given the drug in association with digitalis, diuretics, and vasodilators." | 2.66 | Long-term therapy of chronic congestive heart failure with ibopamine: a multicenter trial. ( Cantoni, V; Cicchetti, V; Ghirardi, P; Marchetti, GV; Rolandi, E; Sabino, F, 1989) |
| "Ibopamine was then administered orally in single doses of 50 mg on day 2 and 100 mg on day 3." | 2.66 | Comparison of the acute hemodynamic effects of ibopamine and dopamine in chronic congestive heart failure. ( Castellaccio, M; Dore, L; Ibba, GV; Sannia, L, 1986) |
| "Chronic heart failure is a complex syndrome: as such it may perhaps be too simplistic to expect any single parameter to be universally predictive of drug effects on mortality, especially when each drug works by different mechanisms." | 2.40 | Can drug effects on mortality in heart failure be predicted by any surrogate measure? ( Struthers, AD; Yee, KM, 1997) |
| "Ibopamine has varying degrees of affinity for these various families, being the highest for the dopamine receptors and the lowest for the alpha adrenergic receptors." | 2.39 | Neurohormonal and hemodynamic effects of ibopamine. ( Pouleur, H, 1995) |
| "Heart failure is a physiopathological condition, with an increasing incidence and prevalence, involving the action of a series of mechanisms known as "compensators", which are phylogenetically ready to normalize minute volume and blood pressure." | 2.39 | [Neurohormonal factors in heart failure (and III)]. ( Cosín Aguilar, J; Cruz Fernández, JM; de Teresa Galván, E; Ferreira Montero, IJ; López-Sendón, J; Soler Soler, J; Tamargo Menéndez, J, 1996) |
| "The crucial issues in the management of congestive heart failure (CHF) are improvement of depressed myocardial contractility and reduction of excessive load." | 2.38 | [New oral drugs for the treatment of congestive heart failure]. ( Hayashida, W; Kawai, C; Kumada, T, 1992) |
| "Ibopamine is a dopamine-like drug that shows mainly vasoactive properties, predominantly acting on dopamine1-(DA1-) and DA2-adrenoceptors." | 2.38 | Ibopamine in chronic congestive heart failure: hemodynamic and neurohumoral effects. ( López-Sendón, J, 1991) |
| " Epinine is intensively metabolized so that less than 1% of the oral dosage is eliminated via the kidneys." | 2.38 | [Ibopamine--pharmacologic principles]. ( Borchard, U, 1991) |
| "Ibopamine has potential in improving prognosis by its major effects: vasodilatation, decrease in vasoactive hormones and improvement in renal blood flow and water diuresis." | 2.38 | [Ibopamine--clinical results]. ( Kleber, FX, 1991) |
| "Ibopamine is able to activate dopamine specific and adrenergic receptors in the heart and circulation, inducing a vasodilating activity together with a mild positive inotropic effect without increasing heart rate and myocardial O2 consumption." | 2.38 | Pharmacological profile of ibopamine. A summary of experiments on anaesthesized dogs. ( Marchetti, GV, 1990) |
| "Ibopamine is an orally active dopaminergic substance and acts mainly as a vasodilator in patients with heart failure." | 2.38 | Effect of ibopamine, a dopamine congener, on arrhythmias in heart failure. ( Storstein, L, 1990) |
| "Ibopamine is a new, orally active dopamine-like drug with inotropic and vasoactive properties." | 2.38 | Hemodynamic and neurohumoral effects of ibopamine in patients with chronic congestive heart failure. ( López-Sendón, J, 1990) |
| " It is concluded that ibopamine is a safe drug which may become an interesting alternative or additive therapy for patients with chronic heart failure." | 2.38 | The safety profile of ibopamine, an alternative substance for treatment of chronic heart failure. ( Holubarsch, C; Just, H, 1990) |
| "Heart failure is a complex cardiovascular syndrome affording many pharmacotherapeutic targets." | 2.38 | Pharmacotherapeutic profile of ibopamine in heart failure. ( Taylor, SH, 1989) |
| " A daily levodopa dosage of at least 4 g appears to a prerequisite for long-term response to the drug." | 2.38 | Clinical relevance of long-term therapy with levodopa and orally active dopamine analogues in patients with chronic congestive heart failure. ( Hasenfuss, G; Just, H, 1989) |
| "Ibopamine was found to increase cardiac output and stroke index and to decrease systemic vascular resistance in this acute study." | 1.28 | Hemodynamic effects and pharmacokinetics of long-term therapy with ibopamine in patients with chronic heart failure. ( Itoh, H; Koike, A; Nakamura, S; Sato, Y; Taniguchi, K; Tsujibayashi, T, 1992) |
| "Ibopamine had a slower but more prolonged effect on cardiac output (increase of up to 32." | 1.28 | Onset of cardiovascular action after oral ibopamine. Early hemodynamic effects of single and repeated doses in patients with idiopathic dilated myocardiopathy. ( Compostella, L; Cucchini, F; Di Mario, C; Ghirardi, P; Iavernaro, A; Libardoni, M, 1990) |
| "Ibopamine is a new orally active dopamine analogue with positive inotropic and vasodilating activity." | 1.28 | Ibopamine: long-term safety study in patients with congestive heart failure. The Italian Ibopamine Working Group. ( Abbondati, G; Cavalli, A; Cedrini, MC; Fuccella, LM; Riva, E; Schleman, M, 1989) |
| " Furthermore, ibopamine-quinidine pharmacokinetic interaction and the effects of food on plasma kinetics were evaluated in NS." | 1.27 | Clinical pharmacokinetics of ibopamine on different diseases and conditions. ( Lodola, E; Ventresca, GP, 1988) |
| "Ibopamine is a new dopamine derivative, active on dopaminergic and beta-adrenergic receptors, whose hemodynamic activity has been acutely demonstrated." | 1.27 | Lack of tolerance development during chronic ibopamine administration to patients with congestive heart failure. ( Dei Cas, L; Manca, C; Metra, M; Nodari, S; Riva, S; Visioli, O, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 56 (37.58) | 18.7374 |
| 1990's | 87 (58.39) | 18.2507 |
| 2000's | 6 (4.03) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Petrie, CJ | 1 |
| Voors, AA | 1 |
| van Veldhuisen, DJ | 17 |
| Goldberg, LI | 4 |
| Rajfer, SI | 4 |
| Ladelli, L | 1 |
| Pezzano, A | 1 |
| Sala, G | 1 |
| Mangiavacchi, M | 3 |
| Cadel, A | 2 |
| Brusoni, B | 4 |
| Reffo, GC | 1 |
| Turrin, M | 1 |
| Gabellini, A | 1 |
| Forattini, C | 1 |
| Col, J | 2 |
| Mievis, E | 1 |
| Reynaert, M | 1 |
| Dei Cas, L | 12 |
| Manca, C | 3 |
| Mansour, M | 1 |
| Vasini, G | 1 |
| Zonca, A | 1 |
| Bernardini, B | 1 |
| Mengeot, P | 1 |
| Piette, F | 1 |
| Mirgaux, M | 1 |
| Walsh, JT | 1 |
| Andrews, R | 2 |
| Evans, A | 2 |
| Cowley, AJ | 4 |
| Cantarelli, MJ | 1 |
| Carvalho, AC | 1 |
| de Almeida, DR | 1 |
| Azevedo, JE | 1 |
| Smith, AC | 1 |
| Campos Filho, O | 1 |
| Martinez Filho, EE | 1 |
| Lieverse, AG | 2 |
| Girbes, AR | 11 |
| Smit, AJ | 7 |
| Zijlstra, JG | 3 |
| Meijer, S | 2 |
| Lie, KI | 11 |
| Reitsma, WD | 3 |
| Brouwer, J | 2 |
| Man in 't Veld, AJ | 3 |
| Dunselman, PH | 3 |
| Boomsma, F | 2 |
| Haaksma, J | 1 |
| Arcensio, SR | 1 |
| Barretto, AC | 1 |
| Szambock, F | 1 |
| Mady, C | 1 |
| Arteaga, E | 1 |
| da Luz, PL | 1 |
| Bellotti, G | 2 |
| Pileggi, F | 1 |
| Metra, M | 11 |
| Missale, C | 2 |
| Spano, PF | 2 |
| Cas, LD | 1 |
| Oosterbosch, C | 1 |
| Francis, GS | 1 |
| Pouleur, H | 4 |
| Holman, ND | 1 |
| Hoekstra, OS | 1 |
| Groeneveld, AB | 1 |
| Schneider, AJ | 1 |
| de Voogt, WG | 1 |
| van der Meer, J | 1 |
| Lok, DJ | 1 |
| Dohmen, HJ | 2 |
| Poortermans, JC | 1 |
| Withagen, AJ | 1 |
| Pasteuning, WH | 2 |
| Rousseau, MF | 3 |
| Konstam, MA | 1 |
| Benedict, CR | 1 |
| Donckier, J | 1 |
| Galanti, L | 1 |
| Melin, J | 1 |
| Kinan, D | 1 |
| Ahn, S | 1 |
| Ketelslegers, JM | 1 |
| van Zwieten, PA | 2 |
| Remme, WJ | 1 |
| Scheen, AJ | 1 |
| Kalisvaart, CJ | 1 |
| Tan, ET | 1 |
| López-Sendón, JL | 1 |
| Said, SA | 1 |
| Bucx, JJ | 1 |
| Dankbaar, H | 1 |
| Huizing, G | 1 |
| van Gilst, WH | 3 |
| Parker, JO | 1 |
| Buikema, H | 1 |
| de Smet, BJ | 1 |
| Scholtens, E | 1 |
| Wesseling, H | 1 |
| van den Broek, SA | 1 |
| de Graeff, PA | 3 |
| Reuge, L | 1 |
| Metzger, J | 1 |
| Burri, M | 1 |
| Kehtari, R | 1 |
| Cosín Aguilar, J | 1 |
| Cruz Fernández, JM | 1 |
| de Teresa Galván, E | 1 |
| Ferreira Montero, IJ | 1 |
| López-Sendón, J | 3 |
| Soler Soler, J | 1 |
| Tamargo Menéndez, J | 1 |
| Szabó, BM | 1 |
| van der Burgh, PH | 1 |
| Kruik, J | 1 |
| Nodari, S | 3 |
| Raccagni, D | 1 |
| Campa, PP | 1 |
| Puddu, PE | 1 |
| Schiariti, M | 1 |
| Monti, F | 1 |
| Dawodu, AA | 1 |
| Gentile, C | 1 |
| Lilla Della Monica, PL | 1 |
| Vaccaro, M | 1 |
| De Biase, L | 1 |
| Niebauer, J | 1 |
| Coats, AJ | 1 |
| Hampton, JR | 4 |
| Kleber, FX | 7 |
| Ardia, A | 1 |
| Block, P | 1 |
| Cortina, A | 2 |
| Cserhalmi, L | 1 |
| Follath, F | 1 |
| Jensen, G | 1 |
| Kayanakis, J | 1 |
| Mancia, G | 1 |
| Skene, AM | 1 |
| Holubarsch, C | 2 |
| Charlesworth, A | 3 |
| Massel, D | 1 |
| Poole-Wilson, PA | 2 |
| Yee, KM | 1 |
| Struthers, AD | 1 |
| Stricker, BH | 3 |
| Feenstra, J | 2 |
| Ottervanger, JP | 1 |
| Porsius, AJ | 1 |
| Grobbee, DE | 2 |
| Naidoo, DP | 1 |
| Rocke, A | 1 |
| Mitha, AS | 1 |
| in't Veld, BA | 2 |
| van der Linden, PD | 1 |
| Elferink, AJ | 1 |
| Lekkerkerker, JF | 1 |
| Vandenbroucke, JP | 1 |
| Febo, O | 1 |
| Cobelli, F | 1 |
| Hillege, HL | 1 |
| de Kam, PJ | 1 |
| de Zeeuw, D | 1 |
| Feenstra, H | 1 |
| Grobbee, RE | 1 |
| Sabin, GV | 1 |
| Thyroff-Friesinger, U | 4 |
| Cabell, B | 1 |
| Glogar, D | 1 |
| Hayashida, W | 1 |
| Kumada, T | 1 |
| Kawai, C | 1 |
| Visioli, O | 4 |
| Raigoso, J | 2 |
| van Eyll, C | 1 |
| Van Mechelen, H | 1 |
| Musso, NR | 1 |
| Lotti, G | 2 |
| Itoh, H | 2 |
| Taniguchi, K | 2 |
| Tsujibayashi, T | 2 |
| Koike, A | 1 |
| Sato, Y | 1 |
| Nakamura, S | 1 |
| Fonseca, C | 1 |
| Gouveia, R | 1 |
| Ceia, F | 1 |
| Mota, E | 1 |
| Coelho, EM | 1 |
| Gil, V | 1 |
| Riva, E | 3 |
| Astorga, MA | 1 |
| Gomes, RS | 1 |
| Luís, AS | 1 |
| Man in't Veld, AJ | 1 |
| Crijns, HJ | 2 |
| Tobé, TJ | 1 |
| Wiesfeld, AC | 1 |
| Borchard, U | 1 |
| Wehling, M | 3 |
| Theisen, K | 3 |
| Costa, R | 1 |
| De Marino, V | 1 |
| Marino, A | 1 |
| Piccini, L | 1 |
| Castelli, N | 1 |
| Mannolini, G | 1 |
| Giannazzo, G | 1 |
| Bordoni, G | 1 |
| Pala, AM | 1 |
| Sher, D | 3 |
| Licciardello, L | 3 |
| Ferrari, V | 3 |
| Sirtori, F | 1 |
| Cesana, B | 1 |
| Barabino, A | 1 |
| Galbariggi, G | 1 |
| Pizzorni, C | 2 |
| Taylor, SH | 2 |
| Cicchetti, V | 6 |
| Marchetti, GV | 5 |
| Storstein, L | 1 |
| Caponnetto, S | 4 |
| Terrachini, V | 3 |
| Canale, C | 3 |
| Bruzzone, F | 2 |
| Masperone, MA | 1 |
| Pastorino, L | 1 |
| Casagrande, C | 2 |
| Merlo, L | 3 |
| La Regina, A | 1 |
| Cocchieri, M | 1 |
| Alunni, GF | 1 |
| Del Favero, A | 1 |
| Fortunati, F | 1 |
| Bardelli, G | 1 |
| Capponi, EA | 1 |
| Regi, L | 1 |
| Boschetti, E | 1 |
| Zimmermann, J | 2 |
| Weil, J | 1 |
| Gerzer, R | 1 |
| Kasmer, RJ | 1 |
| Cutler, RE | 1 |
| Munger, MA | 1 |
| Jarvis, RC | 1 |
| Hricik, D | 1 |
| Nara, AR | 1 |
| Goldberg, P | 1 |
| Green, JA | 1 |
| Just, H | 2 |
| Benzi, L | 1 |
| Sabino, F | 4 |
| Ciccarone, AM | 1 |
| Cecchetti, P | 1 |
| Di Cianni, G | 1 |
| Navalesi, R | 2 |
| Marchetti, P | 1 |
| Giannarelli, R | 1 |
| DiCarlo, A | 1 |
| Azzolini, A | 1 |
| Guffanti, E | 1 |
| Ronzitti, M | 1 |
| Tantalo, L | 1 |
| Colantoni, A | 1 |
| Di Mario, C | 1 |
| Compostella, L | 1 |
| Iavernaro, A | 1 |
| Libardoni, M | 1 |
| Ghirardi, P | 5 |
| Cucchini, F | 1 |
| Ferrini, R | 1 |
| Miragoli, G | 1 |
| Semeraro, C | 1 |
| Sigala, S | 1 |
| Memo, M | 1 |
| Alicandri, C | 1 |
| Fariello, R | 1 |
| Boni, E | 1 |
| Zaninelli, A | 1 |
| Muiesan, G | 1 |
| Rolandi, E | 3 |
| Cantoni, V | 3 |
| Condorelli, M | 1 |
| Bonaduce, A | 1 |
| Montemurro, A | 1 |
| Mattioli, G | 1 |
| Cappello, C | 1 |
| Varricchio, M | 1 |
| Cacciapuoti, F | 1 |
| Longhini, C | 3 |
| Ansani, L | 2 |
| Musacci, GF | 2 |
| Aggio, S | 2 |
| Baracca, E | 2 |
| Toselli, T | 2 |
| Carey, RA | 1 |
| Jacob, L | 1 |
| Hasenfuss, G | 1 |
| Cavalli, A | 2 |
| Schleman, M | 2 |
| Abbondati, G | 2 |
| Fuccella, LM | 2 |
| Cedrini, MC | 1 |
| Barriales, V | 1 |
| Martínez Trabanco, I | 1 |
| Richard, JM | 1 |
| Morimoto, Y | 3 |
| Kasai, A | 1 |
| Nagano, K | 1 |
| Umino, M | 1 |
| Kakuta, Y | 3 |
| Iwata, J | 1 |
| Hamada, M | 1 |
| Konishi, T | 3 |
| Nakano, T | 3 |
| Ventresca, GP | 3 |
| Lodola, E | 2 |
| Stoddard, MF | 1 |
| Chaitman, BR | 1 |
| Byers, SL | 1 |
| Mrosek, D | 1 |
| Labovitz, AJ | 1 |
| Bussmann, WD | 1 |
| Wienhöfer, K | 1 |
| Frik, R | 1 |
| Isaka, N | 1 |
| Tekezawa, H | 1 |
| Kodera, T | 2 |
| Kanamaru, M | 2 |
| Riva, S | 3 |
| Vitolo, E | 1 |
| Segalini, G | 1 |
| Carini, L | 1 |
| Castini, D | 1 |
| Moreo, A | 1 |
| Mazzola, C | 1 |
| Segagni, S | 1 |
| Villa, G | 1 |
| Salvadeo, A | 1 |
| Bianco, L | 2 |
| Azzollini, F | 2 |
| De Caro, L | 1 |
| Longo, A | 2 |
| Pelosi, G | 2 |
| Melloni, R | 1 |
| Scarazatti, E | 1 |
| Gandini, C | 1 |
| Melloni, GF | 1 |
| Partanen, J | 1 |
| Nieminen, MS | 1 |
| Lehto, H | 1 |
| Cattò, G | 1 |
| Iacuitti, G | 1 |
| Picca, M | 1 |
| Pocchiari, F | 2 |
| Pataccini, R | 2 |
| Castelnovo, P | 1 |
| Marchionni, N | 1 |
| Conti, A | 1 |
| De Alfieri, W | 1 |
| Di Bari, M | 1 |
| Ferrucci, L | 1 |
| Lombardi, A | 1 |
| Moschi, G | 1 |
| Vannucci, A | 1 |
| Allegro, A | 1 |
| Cataldi, A | 1 |
| Salvemini, M | 1 |
| Portioli, I | 1 |
| Prati, PL | 1 |
| Gambelli, G | 1 |
| Boccanelli, A | 1 |
| Zacharo, E | 1 |
| Takezawa, H | 1 |
| Marchetti, G | 3 |
| De Vita, C | 1 |
| Triulzi, E | 1 |
| Devizzi, S | 1 |
| Colombo, G | 1 |
| Palvarini, M | 1 |
| Sannia, L | 2 |
| Ibba, GV | 2 |
| Castellaccio, M | 2 |
| Dore, L | 2 |
| Humar, F | 1 |
| Morgera, T | 1 |
| Maras, P | 1 |
| Camerini, F | 1 |
| Gavazzi, A | 1 |
| Mussini, A | 1 |
| Bramucci, E | 1 |
| Pirelli, P | 1 |
| Osculati, G | 1 |
| Rovati, A | 1 |
| Fanciulli, R | 1 |
| Carati, L | 1 |
| Valagussa, F | 1 |
| Barilli, AC | 1 |
| Fracalossi, C | 1 |
| Lomanto, B | 1 |
| Santambrogio, S | 1 |
| Pinca, L | 2 |
| Cavicchi, E | 1 |
| Maggi, GC | 2 |
| Avanzini, Z | 1 |
| Bellogini, GC | 1 |
| Ciampani, N | 1 |
| Gazzola, U | 1 |
| Scorcu, G | 1 |
| Rossen, JD | 1 |
| Douglas, FL | 1 |
| Karrison, T | 1 |
| Franceschini, R | 1 |
| Gianrossi, R | 1 |
| Barreca, T | 1 |
| Fappani, A | 2 |
| Cicogna, R | 1 |
| Giunti, G | 1 |
| Faggiano, P | 1 |
| Ferrari, R | 1 |
| La Canna, G | 1 |
| Zanini, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Intravenous Levosimendan Compared With Dobutamine on Renal Hemodynamics and Function in Chronic Heart Failure[NCT02133105] | Phase 3 | 33 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
29 reviews available for deoxyepinephrine and Heart Failure
| Article | Year |
|---|---|
Receptor systems involved in norepinephrine release in heart failure: focus on dopaminergic systems.
Topics: Deoxyepinephrine; Dopamine Agonists; Heart Failure; Humans; Norepinephrine; Receptors, Dopamine | 1995 |
Neurohormonal and hemodynamic effects of ibopamine.
Topics: Clinical Trials as Topic; Deoxyepinephrine; Dopamine Agonists; Heart Failure; Hemodynamics; Humans; | 1995 |
Clinical efficacy of ibopamine in patients with chronic heart failure.
Topics: Clinical Trials as Topic; Deoxyepinephrine; Dopamine Agonists; Heart Failure; Hemodynamics; Humans; | 1995 |
[Neurohormonal compensation processes in chronic heart failure: the effect of drugs].
Topics: Adrenergic beta-Agonists; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Cardiac Glycosid | 1994 |
[Chronic cardiac insufficiency: current treatment and future outlook].
Topics: Adrenergic Antagonists; Aldosterone; Angiotensin II; Cardiotonic Agents; Cardiovascular Agents; Clin | 1996 |
[Neurohormonal factors in heart failure (and III)].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiotonic Agents; Clinical | 1996 |
Can drug effects on mortality in heart failure be predicted by any surrogate measure?
Topics: Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Biomarkers; Calcium Ch | 1997 |
Dopamine in heart failure and critical care.
Topics: Cardiotonic Agents; Controlled Clinical Trials as Topic; Critical Care; Deoxyepinephrine; Dopamine; | 2000 |
[Exercise test in the evaluation of the efficacy of drug therapy].
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Calcium Chann | 2000 |
The underreporting of results and possible mechanisms of 'negative' drug trials in patients with chronic heart failure.
Topics: Bosentan; Cardiovascular Agents; Deoxyepinephrine; Heart Failure; Humans; Imidazoles; Mibefradil; Py | 2001 |
[New oral drugs for the treatment of congestive heart failure].
Topics: Administration, Oral; Cardiotonic Agents; Deoxyepinephrine; Ethanolamines; Heart Failure; Humans; Ph | 1992 |
Ibopamine in the treatment of heart failure.
Topics: Cardiotonic Agents; Deoxyepinephrine; Dopamine Agents; Heart Failure; Humans; Vasodilator Agents | 1991 |
Ibopamine in chronic congestive heart failure: hemodynamic and neurohumoral effects.
Topics: Animals; Cardiotonic Agents; Deoxyepinephrine; Dopamine Agents; Heart; Heart Failure; Hemodynamics; | 1991 |
[Ibopamine--pharmacologic principles].
Topics: Cardiotonic Agents; Deoxyepinephrine; Dopamine Agents; Heart; Heart Failure; Hemodynamics; Humans; R | 1991 |
[Ibopamine--clinical results].
Topics: Cardiotonic Agents; Deoxyepinephrine; Dopamine Agents; Heart; Heart Failure; Hemodynamics; Humans; K | 1991 |
[Ibopamine--acute hemodynamic, renal and neurohumoral effects].
Topics: Cardiotonic Agents; Deoxyepinephrine; Dopamine Agents; Heart; Heart Failure; Hemodynamics; Hormones; | 1991 |
[Physiological bases and therapeutic uses of inodilator drugs].
Topics: Amrinone; Cardiotonic Agents; Deoxyepinephrine; Dobutamine; Dopamine; Heart Failure; Humans; Milrino | 1991 |
Efficacy of ibopamine in the treatment of heart failure.
Topics: Cardiotonic Agents; Deoxyepinephrine; Dopamine Agents; Heart Failure; Humans; Vasodilator Agents | 1990 |
Pharmacological profile of ibopamine. A summary of experiments on anaesthesized dogs.
Topics: Animals; Cardiotonic Agents; Deoxyepinephrine; Dogs; Dopamine Agents; Dose-Response Relationship, Dr | 1990 |
Effect of ibopamine, a dopamine congener, on arrhythmias in heart failure.
Topics: Animals; Cardiotonic Agents; Deoxyepinephrine; Dopamine Agents; Electrocardiography, Ambulatory; Hea | 1990 |
Hemodynamic and neurohumoral effects of ibopamine in patients with chronic congestive heart failure.
Topics: Cardiotonic Agents; Deoxyepinephrine; Drug Therapy, Combination; Heart Failure; Hemodynamics; Humans | 1990 |
Development of dopaminergic drugs for the chronic treatment of congestive heart failure.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Deoxyepinephrine; Dopamine; Dop | 1990 |
How to select a drug for the long-term treatment of chronic heart failure.
Topics: Cardiotonic Agents; Deoxyepinephrine; Heart Failure; Humans | 1990 |
The safety profile of ibopamine, an alternative substance for treatment of chronic heart failure.
Topics: Cardiotonic Agents; Deoxyepinephrine; Electrocardiography; Heart Failure; Hemodynamics; Humans; Vaso | 1990 |
Pharmacotherapeutic profile of ibopamine in heart failure.
Topics: Adrenergic beta-Agonists; Aged; Cardiotonic Agents; Deoxyepinephrine; Dopamine; Dopamine Agents; Hea | 1989 |
Cardiovascular and renal action of dopaminergic prodrugs.
Topics: Animals; Cardiotonic Agents; Cats; Chemical Phenomena; Chemistry; Deoxyepinephrine; Dihydroxyphenyla | 1989 |
The role of dopaminergic agents and the dopamine receptor in treatment for CHF.
Topics: Benzazepines; Deoxyepinephrine; Dobutamine; Dopamine; Dopamine Agents; Fenoldopam; Heart Failure; Hu | 1989 |
Clinical relevance of long-term therapy with levodopa and orally active dopamine analogues in patients with chronic congestive heart failure.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Administration, Oral; Chronic Disease; D | 1989 |
Ibopamine--how should it be used?
Topics: Cardiotonic Agents; Clinical Trials as Topic; Deoxyepinephrine; Dopamine; Heart Failure; Hemodynamic | 1988 |
51 trials available for deoxyepinephrine and Heart Failure
| Article | Year |
|---|---|
Low pulse pressure is an independent predictor of mortality and morbidity in non ischaemic, but not in ischaemic advanced heart failure patients.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Blood Pressure; Deoxyepinephrine; | 2009 |
[Echocardiographic and polygraphic study of acute/effects of Ibopamine on cardiac performance].
Topics: Adult; Cardiotonic Agents; Deoxyepinephrine; Dopamine; Echocardiography; Heart; Heart Failure; Hemod | 1983 |
Failure of "effective" treatment for heart failure to improve normal customary activity.
Topics: Activities of Daily Living; Aged; Angiotensin-Converting Enzyme Inhibitors; Captopril; Chronic Disea | 1995 |
[Acute hemodynamic effects of ibopamine, captopril, and placebo in patients with severe heart failure].
Topics: Adolescent; Adult; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Captopril; Cardio | 1995 |
Heart rate variability in patients with mild to moderate heart failure: effects of neurohormonal modulation by digoxin and ibopamine. The Dutch Ibopamine Multicenter Trial (DIMT) Study Group.
Topics: Aldosterone; Cardiotonic Agents; Deoxyepinephrine; Digoxin; Diuretics; Dopamine Agonists; Double-Bli | 1995 |
[Comparative study between ibopamine and captopril in mild and moderate heart failure. A double-blind study].
Topics: Adult; Aged; Captopril; Cardiotonic Agents; Clinical Protocols; Deoxyepinephrine; Double-Blind Metho | 1994 |
Dopaminergic drugs in congestive heart failure: hemodynamic and neuroendocrine responses to ibopamine, dopamine, and dihydroergotoxine.
Topics: Administration, Oral; Aged; Aldosterone; Analysis of Variance; Blood Pressure; Deoxyepinephrine; Dih | 1995 |
Renal and systemic hemodynamic effects of ibopamine in patients with mild to moderate congestive heart failure.
Topics: Aged; Aldosterone; Deoxyepinephrine; Female; Heart Failure; Hemodynamics; Humans; Kidney Function Te | 1995 |
Acute effect of ibopamine and isosorbide mononitrate on blood volume distribution in congestive heart failure.
Topics: Aged; Blood Volume; Deoxyepinephrine; Double-Blind Method; Drug Interactions; Female; Heart Failure; | 1994 |
Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT).
Topics: Adolescent; Adult; Aged; Aldosterone; Cardiotonic Agents; Deoxyepinephrine; Digoxin; Dopamine Agents | 1993 |
Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor.
Topics: Aged; Coronary Disease; Deoxyepinephrine; Dopamine Agents; Double-Blind Method; Down-Regulation; Dru | 1994 |
The effects of oral ibopamine in patients with mild heart failure--a double blind placebo controlled comparison to furosemide. The Ibopamine Study Group.
Topics: Administration, Oral; Adolescent; Adult; Aged; Cardiac Output; Cardiotonic Agents; Child; Deoxyepine | 1993 |
Clinical and autonomic effects of ibopamine as adjunct to angiotensin-converting enzyme inhibitors in chronic heart failure.
Topics: Aged; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Autonomic Nervous System; Blood Gas Ana | 1996 |
Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators.
Topics: Adult; Aged; Aged, 80 and over; Cause of Death; Deoxyepinephrine; Dopamine Agonists; Female; Follow- | 1997 |
A double-blind, cross-over comparison of the effects of a loop diuretic and a dopamine receptor agonist as first line therapy in patients with mild congestive heart failure.
Topics: Adult; Cross-Over Studies; Deoxyepinephrine; Diuretics; Dopamine Agonists; Double-Blind Method; Exer | 1997 |
Ibopamine and survival in severe congestive heart failure: PRIME II.
Topics: Cardiotonic Agents; Cause of Death; Deoxyepinephrine; Drug Monitoring; Heart Failure; Humans; Placeb | 1997 |
Ibopamine and survival in severe congestive heart failure: PRIME II.
Topics: Amiodarone; Anti-Arrhythmia Agents; Area Under Curve; Cardiotonic Agents; Cause of Death; Deoxyepine | 1997 |
Comparison of captopril and ibopamine in mild to moderate heart failure.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Captopril; Deoxyepinephrine; Dopamine Agonist | 1997 |
Evaluation of ibopamine plus prazosin in congestive heart failure.
Topics: Adrenergic alpha-Antagonists; Adult; Cross-Over Studies; Deoxyepinephrine; Double-Blind Method; Drug | 1998 |
Renal function, neurohormonal activation, and survival in patients with chronic heart failure.
Topics: Aged; Aldosterone; Atrial Natriuretic Factor; Cardiac Output; Cardiotonic Agents; Catecholamines; Ch | 2000 |
Achieving appropriate endpoints in heart failure trials: the PRIME-II protocol. The Second Perspective Randomised study of Ibopamine on Mortality and Efficacy.
Topics: Clinical Protocols; Deoxyepinephrine; Evaluation Studies as Topic; Heart Failure; Humans; Patient Se | 1999 |
Effects of acute and chronic ibopamine administration on resting and exercise hemodynamics, plasma catecholamines and functional capacity of patients with chronic congestive heart failure.
Topics: Deoxyepinephrine; Dopamine Agents; Double-Blind Method; Epinephrine; Exercise; Female; Heart Failure | 1992 |
[Ibopamine in the treatment of congestive heart failure. Multicenter follow-up study].
Topics: Adult; Aged; Aged, 80 and over; Cardiotonic Agents; Deoxyepinephrine; Drug Evaluation; Female; Heart | 1992 |
Hemodynamic comparison of combined therapy by nitroglycerin tape and ibopamine with combination of nitroglycerin tape and nifedipine.
Topics: Administration, Cutaneous; Administration, Oral; Cardiac Complexes, Premature; Cardiotonic Agents; D | 1990 |
[Ibopamine in treatment of mild heart failure, a comparison with hydrochlorothiazide].
Topics: Aged; Cardiotonic Agents; Deoxyepinephrine; Double-Blind Method; Drug Therapy, Combination; Female; | 1991 |
Safety of ibopamine therapy in congestive heart failure. Ibopamine cohort study: baseline and 1-year results.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angina Pectoris; Arrhythmias, Cardiac; Blood Pressure; C | 1991 |
Comparative effects of long-term therapy with captopril and ibopamine in chronic congestive heart failure in old patients.
Topics: Aged; Captopril; Deoxyepinephrine; Double-Blind Method; Exercise Test; Female; Follow-Up Studies; He | 1991 |
Comparative effects of ibopamine and captopril in mild congestive heart failure. Focus on the long-term effects of inodilation on ventricular arrhythmias.
Topics: Adult; Aged; Captopril; Cardiotonic Agents; Deoxyepinephrine; Double-Blind Method; Drug Therapy, Com | 1990 |
[Renal effects of ibopamine in comparison with furosemide in patients with mild heart failure].
Topics: Atrial Natriuretic Factor; Blood Pressure; Cardiomyopathy, Dilated; Coronary Disease; Cyclic GMP; De | 1990 |
Single-dose effects of ibopamine hydrochloride on renal function in patients with congestive heart failure.
Topics: Acute Kidney Injury; Administration, Oral; Aged; Deoxyepinephrine; Diuretics; Female; Heart Failure; | 1990 |
Ibopamine does not affect insulin resistance in patients with type I diabetes.
Topics: Adult; Blood Glucose; Cardiotonic Agents; Deoxyepinephrine; Diabetes Mellitus, Type 1; Female; Heart | 1990 |
Safety of ibopamine in type II diabetic patients with mild chronic heart failure. A double-blind cross-over study.
Topics: Aged; C-Peptide; Cardiotonic Agents; Deoxyepinephrine; Diabetes Mellitus, Type 2; Double-Blind Metho | 1990 |
Treatment of mild chronic congestive heart failure with ibopamine, hydrochlorothiazide, ibopamine plus hydrochlorothiazide or placebo. A double-blind comparative study.
Topics: Adult; Aged; Aged, 80 and over; Cardiotonic Agents; Deoxyepinephrine; Double-Blind Method; Female; H | 1990 |
Ibopamine versus digoxin in the treatment of mild congestive heart failure. A double-blind, randomized, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Cardiotonic Agents; Deoxyepinephrine; Digoxin; Double-Blind Method; | 1990 |
Extracardial effects of oral ibopamine versus furosemide in patients with mild or moderate heart failure. A double-blind, randomized trial.
Topics: Administration, Oral; Adult; Cardiotonic Agents; Deoxyepinephrine; Double-Blind Method; Female; Furo | 1990 |
Ibopamine in the treatment of mild chronic heart failure in elderly patients. A double-blind, placebo-controlled study.
Topics: Aged; Cardiotonic Agents; Deoxyepinephrine; Double-Blind Method; Exercise Test; Female; Heart Failur | 1990 |
Absence of proarrhythmic effects of ibopamine in patients with congestive heart failure.
Topics: Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Cardiotonic Agen | 1989 |
Inhibition of aldosterone secretion by dopamine, ibopamine, and dihydroergotoxine in patients with congestive heart failure.
Topics: Aged; Aldosterone; Deoxyepinephrine; Depression, Chemical; Dihydroergotoxine; Dopamine; Dopamine Age | 1989 |
Ibopamine vs. digoxin in chronic heart failure: a double-blind, crossover study.
Topics: Adult; Aged; Cardiotonic Agents; Chronic Disease; Deoxyepinephrine; Digoxin; Dopamine; Double-Blind | 1989 |
Long-term therapy of chronic congestive heart failure with ibopamine: a multicenter trial.
Topics: Adult; Aged; Aged, 80 and over; Cardiotonic Agents; Chronic Disease; Deoxyepinephrine; Dopamine; Dru | 1989 |
The long-term efficacy of ibopamine in treating patients with severe heart failure: a multicenter investigation.
Topics: Adult; Aged; Aged, 80 and over; Cardiotonic Agents; Clinical Trials as Topic; Deoxyepinephrine; Digi | 1989 |
Peripheral hemodynamic effects of ibopamine in patients with congestive heart failure. A placebo-controlled, double-blind study.
Topics: Aged; Aged, 80 and over; Deoxyepinephrine; Double-Blind Method; Female; Heart Failure; Heart Rate; H | 1989 |
Ibopamine versus hydrochlorothiazide/amiloride in patients with mild congestive heart failure. SK & F Ibopamine Working Group.
Topics: Amiloride; Body Weight; Cardiotonic Agents; Deoxyepinephrine; Double-Blind Method; Drug Combinations | 1989 |
Influence of ibopamine on heart rate and arrhythmic pattern in patients with congestive heart failure. A double-blind multicentre study.
Topics: Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Cardiotonic Agents; Deoxyepinephrine; Dopamine | 1989 |
Ibopamine as a substitute for digitalis in patients with congestive heart failure on chronic digoxin therapy. Smith Kline and French Ibopamine Group.
Topics: Adult; Aged; Arrhythmias, Cardiac; Deoxyepinephrine; Digoxin; Dopamine; Echocardiography; Exercise T | 1989 |
Ibopamine--how should it be used?
Topics: Cardiotonic Agents; Clinical Trials as Topic; Deoxyepinephrine; Dopamine; Heart Failure; Hemodynamic | 1988 |
Effects of ibopamine in combination with furosemide on renal function in patients with chronic congestive heart failure.
Topics: Aged; Blood Glucose; Chlorides; Creatinine; Deoxyepinephrine; Dopamine; Drug Therapy, Combination; E | 1988 |
Positive inotropic effects of ibopamine in patients with congestive heart failure. A multicenter investigation.
Topics: Adult; Aged; Blood Chemical Analysis; Cardiotonic Agents; Clinical Trials as Topic; Deoxyepinephrine | 1986 |
Ibopamine post-marketing surveillance. First report from a parallel-cohorts survey ongoing since April 1st, 1985.
Topics: Aged; Angina Pectoris; Arrhythmias, Cardiac; Cardiotonic Agents; Cardiovascular Diseases; Deoxyepine | 1987 |
Comparison of the acute hemodynamic effects of ibopamine and dopamine in chronic congestive heart failure.
Topics: Adult; Cardiac Output; Cardiotonic Agents; Chronic Disease; Deoxyepinephrine; Dopamine; Heart Failur | 1986 |
Effects of digoxin, placebo and ibopamine on exercise tolerance and cardiac rhythm of patients with chronic post-infarct left ventricular failure.
Topics: Aged; Arrhythmias, Cardiac; Cardiotonic Agents; Deoxyepinephrine; Digoxin; Dopamine; Female; Heart F | 1986 |
70 other studies available for deoxyepinephrine and Heart Failure
| Article | Year |
|---|---|
Sympathomimetic amines: potential clinical applications in ischemic heart disease.
Topics: Animals; Coronary Disease; Deoxyepinephrine; Dobutamine; Dogs; Dopamine; Heart Failure; Humans; Levo | 1982 |
Haemodynamic evaluation of ibopamine in severe congestive heart failure.
Topics: Adult; Aged; Blood Pressure; Cardiac Catheterization; Cardiac Output; Cardiotonic Agents; Deoxyepine | 1984 |
Ibopamine in very severe congestive heart failure: pilot haemodynamic invasive assessment.
Topics: Aged; Blood Pressure; Cardiac Output; Deoxyepinephrine; Diuretics; Dopamine; Heart Failure; Hemodyna | 1983 |
[Preliminary results of the action of long-term oral treatment with the di-isobutyric ester of N-methyldopamine (SB 7505) in 10 patients with severe cardiocirculatory decompensation].
Topics: Aged; Aortic Valve; Blood Pressure; Cardiomyopathies; Deoxyepinephrine; Diuresis; Diuretics; Dopamin | 1980 |
Double-blind haemodynamic study of a new dopamine derivative (diisobutyric ester of N-methyl-dopamine) orally active in chronic congestive heart failure.
Topics: Aged; Blood Pressure; Deoxyepinephrine; Dopamine; Double-Blind Method; Female; Heart Failure; Heart | 1981 |
The effects of ibopamine on glomerular filtration rate and plasma norepinephrine remain preserved during prolonged treatment in patients with congestive heart failure.
Topics: Adult; Aged; Aldosterone; Deoxyepinephrine; Dopamine Agonists; Dose-Response Relationship, Drug; Dru | 1995 |
Pharmacologic treatment of congestive heart failure.
Topics: Cardiotonic Agents; Deoxyepinephrine; Diuretics; Heart Failure; Humans; Vasodilator Agents | 1995 |
Congestive heart failure. Drug therapy: central or peripheral approach?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiotonic Agents; Carnitine | 1993 |
[Drug of the month. Ibopamine (Scandine, Idopamil)].
Topics: Cardiotonic Agents; Deoxyepinephrine; Heart Failure; Humans; Vasodilator Agents | 1994 |
Effects of ibopamine on renal haemodynamics in patients with severe congestive heart failure.
Topics: Aged; Aged, 80 and over; Deoxyepinephrine; Dopamine Agents; Drug Evaluation; Glomerular Filtration R | 1993 |
[The neurohumoral mechanisms are already altered before the patient may have symptoms of heart failure. Interview by Salvador Giménez].
Topics: Deoxyepinephrine; Dopamine Agents; Heart Failure; Humans; Neurotransmitter Agents | 1993 |
Ibopamine-induced reversible leukopenia during treatment for congestive heart failure.
Topics: Aged; Aged, 80 and over; Deoxyepinephrine; Dopamine Agents; Female; Heart Failure; Humans; Leukopeni | 1993 |
Endothelium dependent relaxation in two different models of chronic heart failure and the effect of ibopamine.
Topics: Animals; Aortic Valve Stenosis; Culture Techniques; Deoxyepinephrine; Disease Models, Animal; Endoth | 1993 |
Effects of ibopamine on the increase in plasma norepinephrine levels during exercise in congestive heart failure.
Topics: Adult; Aged; Aged, 80 and over; Cardiotonic Agents; Deoxyepinephrine; Female; Heart Failure; Humans; | 1993 |
[Clinical efficacy of oral dopaminergic agents: new findings].
Topics: Administration, Oral; Adrenergic alpha-Agonists; Deoxyepinephrine; Dopamine; Dopamine Agents; Dopami | 1995 |
[Refractory heart failure: it requires the use of polychemotherapy. What is the rationale?].
Topics: Adrenergic Agonists; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiomy | 1995 |
Treating chronic heart failure: time to take stock.
Topics: Chronic Disease; Deoxyepinephrine; Dopamine Agonists; Heart Failure; Humans; Randomized Controlled T | 1997 |
New inotropic concepts: rationale for and differences between calcium sensitizers and phosphodiesterase inhibitors.
Topics: Animals; Calcium; Cardiotonic Agents; Deoxyepinephrine; Energy Metabolism; Guinea Pigs; Heart Failur | 1997 |
Treatment of mild heart failure: the place of diuretics and ibopamine.
Topics: Chronic Disease; Deoxyepinephrine; Diuretics; Dopamine Agonists; Drug Therapy, Combination; Heart Fa | 1997 |
PRIME II (Second Prospective Randomized Study of Ibupamine on Mortality and Efficacy): another disappointment in heart failure therapy.
Topics: Deoxyepinephrine; Dopamine Agonists; Drug Evaluation; Heart Failure; Humans; Multicenter Studies as | 1997 |
Dopamine agonists in heart failure: an untimely death.
Topics: Deoxyepinephrine; Dopamine Agonists; Heart Failure; Humans; Netherlands | 1997 |
A nested case-control study on mortality in users of ibopamine.
Topics: Aged; Case-Control Studies; Deoxyepinephrine; Dopamine Agonists; Female; Heart Failure; Humans; Logi | 1997 |
Risk factors for mortality in users of ibopamine.
Topics: Aged; Cohort Studies; Deoxyepinephrine; Dopamine Agonists; Female; Heart Failure; Humans; Male; Midd | 1998 |
[Risk factors for dying among ibopamine users].
Topics: Adult; Aged; Cardiotonic Agents; Clinical Trials as Topic; Deoxyepinephrine; Female; Heart Failure; | 1999 |
[Risk factors for dying among ibopamine users].
Topics: Aged; Cardiotonic Agents; Clinical Trials as Topic; Deoxyepinephrine; Heart Failure; Humans; Risk Fa | 1999 |
Confounding by contraindication in a nationwide cohort study of risk for death in patients taking ibopamine.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Cohort Studies; Confounding Factors, Epidemiologic; C | 2001 |
Ibopamine as a valuable adjunct and substitute for dopamine in bridging therapy before heart transplantation.
Topics: Adult; Cardiotonic Agents; Deoxyepinephrine; Dopamine; Drug Therapy, Combination; Female; Heart Fail | 1992 |
Effects of intravenous epinine administration on left ventricular systolic performance, coronary hemodynamics, and circulating catecholamines in patients with heart failure.
Topics: Adult; Aged; Catecholamines; Coronary Circulation; Deoxyepinephrine; Female; Heart Failure; Hemodyna | 1992 |
Hemodynamic effects and pharmacokinetics of long-term therapy with ibopamine in patients with chronic heart failure.
Topics: Administration, Oral; Aged; Cardiotonic Agents; Chronic Disease; Deoxyepinephrine; Dose-Response Rel | 1992 |
Ibopamine: a new pharmacotherapeutic approach to heart failure. Proceedings of a symposium. October 19, 1989, Kyoto, Japan.
Topics: Deoxyepinephrine; Dopamine Agents; Heart Failure; Humans | 1991 |
Dopaminergic drugs in the management of chronic heart failure.
Topics: Adult; Deoxyepinephrine; Dopamine Agents; Female; Heart Failure; Hemodynamics; Humans; Levodopa; Mal | 1991 |
Electrophysiologic profile of ibopamine in patients with congestive heart failure and ventricular tachycardia and relation to its effects on hemodynamics and plasma catecholamines.
Topics: Adult; Aged; Blood Pressure; Cardiac Pacing, Artificial; Catecholamines; Deoxyepinephrine; Dopamine | 1991 |
Dopamine agonists, a new perspective in cardiovascular therapy?
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Deoxyepinephrine; Dopamine Agents; Fenol | 1991 |
[Changes in the cardio-thoracic index during the treatment with ibopamine].
Topics: Administration, Oral; Aged; Aged, 80 and over; Cardiotonic Agents; Deoxyepinephrine; Female; Heart F | 1991 |
[Dopamine and dopaminergic drugs as therapeutic agents in heart failure].
Topics: Deoxyepinephrine; Dobutamine; Dopamine; Dopamine Agents; Heart Failure; Hemodynamics; Humans; Vasodi | 1990 |
Long-term treatment of congestive heart failure with oral ibopamine. Effects of rhythm disorders and neurohormonal alterations.
Topics: Administration, Oral; Aged; Aldosterone; Angiotensin II; Arrhythmias, Cardiac; Cardiotonic Agents; D | 1990 |
Efficacy and safety of ibopamine in congestive heart failure.
Topics: Adult; Aged; Aged, 80 and over; Deoxyepinephrine; Dopamine Agents; Drug Evaluation; Electrocardiogra | 1990 |
Ibopamine in the management of congestive heart failure.
Topics: Deoxyepinephrine; Heart Failure; Humans | 1990 |
Onset of cardiovascular action after oral ibopamine. Early hemodynamic effects of single and repeated doses in patients with idiopathic dilated myocardiopathy.
Topics: Aged; Blood Pressure; Cardiac Output; Cardiomyopathy, Dilated; Deoxyepinephrine; Dopamine; Female; H | 1990 |
Efficacy of ibopamine treatment in patients with advanced heart failure: purpose of a new therapeutic scheme with multiple daily administrations.
Topics: Administration, Oral; Adult; Cardiotonic Agents; Creatinine; Deoxyepinephrine; Dopamine; Drug Admini | 1989 |
Ibopamine: long-term safety study in patients with congestive heart failure. The Italian Ibopamine Working Group.
Topics: Adolescent; Adult; Aged; Cardiotonic Agents; Demography; Deoxyepinephrine; Diuretics; Dopamine; Drug | 1989 |
[Role of ibopamine in cardiac insufficiency in auricular fibrillation. Presentation of a case].
Topics: Aged; Atrial Fibrillation; Cardiotonic Agents; Deoxyepinephrine; Dopamine; Heart Failure; Humans; Ma | 1989 |
[Acute and chronic effects of a new oral inotropic agent, ibopamine hydrochloride, on hemodynamic and metabolic responses to ergometer exercise in patients with severe congestive heart failure].
Topics: Administration, Oral; Adult; Aged; Cardiotonic Agents; Deoxyepinephrine; Exercise Test; Female; Hear | 1989 |
Dopamine receptors: applications in clinical cardiology.
Topics: Administration, Oral; Arrhythmias, Cardiac; Benzazepines; Bromocriptine; Deoxyepinephrine; Fenoldopa | 1985 |
The role of adrenergic and dopamine receptors.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Cardiotonic Agents | 1985 |
Clinical pharmacokinetics of ibopamine on different diseases and conditions.
Topics: Absorption; Administration, Oral; Adult; Aged; Aged, 80 and over; Biological Availability; Chemical | 1988 |
Noninvasive assessment of diastolic and systolic properties of ibopamine in patients with congestive heart failure.
Topics: Adult; Aged; Deoxyepinephrine; Diastole; Dopamine; Echocardiography; Echocardiography, Doppler; Hear | 1989 |
[Acute effects of ibopamine hydrochloride on hemodynamics, plasma catecholamine levels, renin activity, aldosterone, metabolism and blood gas in patients with severe congestive heart failure].
Topics: Aged; Aged, 80 and over; Aldosterone; Carbon Dioxide; Cardiotonic Agents; Catecholamines; Deoxyepine | 1987 |
Lack of tolerance development during chronic ibopamine administration to patients with congestive heart failure.
Topics: Adult; Aged; Chronic Disease; Deoxyepinephrine; Drug Tolerance; Heart Failure; Humans; Male; Middle | 1988 |
Treatment of heart failure following chronic cor pulmonale with ibopamine.
Topics: Aged; Aged, 80 and over; Chronic Disease; Deoxyepinephrine; Diuretics; Dopamine; Dose-Response Relat | 1988 |
Ibopamine kinetics after single and multiple dosing in patients with congestive heart failure.
Topics: Aged; Deoxyepinephrine; Dopamine; Drug Administration Schedule; Female; Heart Failure; Humans; Male; | 1988 |
[Blood levels of activated renin, aldosterone, catecholamine in congestive heart failure. II. Effects of dopaminergic stimulation with a dopamine agonist: ibopamine].
Topics: Adult; Aldosterone; Blood Volume; Catecholamines; Deoxyepinephrine; Dopamine; Female; Heart Failure; | 1987 |
Effect of ibopamine on the failing heart at rest and during isometric exercise: a noninvasive study.
Topics: Adult; Cardiotonic Agents; Deoxyepinephrine; Dopamine; Heart Failure; Hemodynamics; Humans; Isometri | 1988 |
Ibopamine kinetics after a single oral dose in patients with congestive heart failure.
Topics: Administration, Oral; Adult; Aged; Chromatography, High Pressure Liquid; Deoxyepinephrine; Dopamine; | 1988 |
Ibopamine in congestive heart failure refractory to digitalis, diuretics, and captopril.
Topics: Aged; Captopril; Cardiotonic Agents; Creatinine; Deoxyepinephrine; Digitalis Glycosides; Diuretics; | 1986 |
Acute effects of ibopamine hydrochloride on hemodynamics, plasma catecholamine levels, renin activity, aldosterone, metabolism and blood gas in patients with severe congestive heart failure.
Topics: Aged; Aldosterone; Blood Gas Analysis; Cardiotonic Agents; Catecholamines; Deoxyepinephrine; Dopamin | 1986 |
Effects of ibopamine on acute cardiac failure following experimental coronary occlusion in dogs.
Topics: Animals; Cardiotonic Agents; Coronary Disease; Deoxyepinephrine; Dogs; Dopamine; Electrocardiography | 1986 |
Evaluation of acute hemodynamic effects and pharmacokinetic behaviour of ibopamine in patients with severe heart failure.
Topics: Adult; Aged; Deoxyepinephrine; Diuretics; Dopamine; Echocardiography; Female; Heart Failure; Hemodyn | 1986 |
Hemodynamic evaluation of ibopamine in patients with refractory congestive heart failure.
Topics: Adult; Aged; Cardiac Catheterization; Cardiotonic Agents; Deoxyepinephrine; Dopamine; Drug Resistanc | 1986 |
Hemodynamic evaluation during exercise test after acute and chronic ibopamine treatment in patients with congestive heart failure.
Topics: Adult; Aged; Cardiac Catheterization; Cardiotonic Agents; Deoxyepinephrine; Dopamine; Exercise Test; | 1986 |
Effects of ibopamine on peripheral hemodynamics: a strain gauge plethysmographic study in patients with congestive heart failure.
Topics: Aged; Blood Pressure; Cardiotonic Agents; Deoxyepinephrine; Dopamine; Female; Heart Failure; Hemodyn | 1986 |
Multicenter study on the clinical efficacy of chronic ibopamine administration.
Topics: Aged; Blood Pressure; Cardiotonic Agents; Deoxyepinephrine; Diuresis; Dopamine; Female; Heart Failur | 1986 |
Monitored long-term treatment with ibopamine in patients suffering from severe congestive heart failure.
Topics: Adult; Aged; Body Weight; Cardiotonic Agents; Chronic Disease; Deoxyepinephrine; Dopamine; Female; H | 1986 |
A survey of 311 patients receiving ibopamine mainly during hospital treatment for severe congestive heart failure.
Topics: Age Factors; Aged; Blood Pressure; Body Weight; Cardiotonic Agents; Deoxyepinephrine; Dopamine; Fema | 1986 |
[Comparison of the acute effects of ibopamine with those of dopamine on the echocardiographic parameters of systolic function of the heart in congestive cardiac failure].
Topics: Adult; Aged; Deoxyepinephrine; Dopamine; Echocardiography; Heart Failure; Humans; Male; Middle Aged; | 1986 |
Effects of long-term therapy with oral ibopamine on resting hemodynamics and exercise capacity in patients with heart failure: relationship to the generation of N-methyldopamine and to plasma norepinephrine levels.
Topics: Administration, Oral; Cardiac Output; Deoxyepinephrine; Dopamine; Female; Heart Failure; Hemodynamic | 1986 |
Inhibition of prolactin and aldosterone secretion by the dopamine derivative ibopamine.
Topics: Adult; Aldosterone; Deoxyepinephrine; Dopamine; Female; Growth Hormone; Heart Failure; Humans; Hydro | 1986 |
Acute haemodynamic effects of ibopamine in patients with severe congestive heart failure.
Topics: Adult; Aged; Cardiac Catheterization; Cardiotonic Agents; Deoxyepinephrine; Dopamine; Female; Heart | 1985 |
Hemodynamic advantage of combined administration of oral ibopamine and nitroprusside in patients with ischemic and idiopathic congestive cardiomyopathy.
Topics: Adult; Aged; Cardiomyopathy, Dilated; Cardiotonic Agents; Coronary Disease; Deoxyepinephrine; Dopami | 1985 |
[Hemodynamic effects induced by the combined administration of sodium nitroprusside and ibopamine in patients with congestive heart decompensation].
Topics: Adult; Aged; Cardiotonic Agents; Deoxyepinephrine; Dopamine; Drug Therapy, Combination; Female; Ferr | 1985 |